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Chapter I 
Review of literature and scope of this thesis 
In this first chapter the current insights are reviewed on what is known about 
the regulation of the hypothalamo-pituitary-adrenal axis (HPA-axis). This in-
troductory chapter has been divided in three different sections. 
The first section (A) reviews the literature concerning the effects of gluco-
corlicoids on the function and the regulation of the HP A-axis. The second 
part (B) focuses on the nature and the regulation of corticotropin-releasing-
factor (CRF). Finally, in the third section of this chapter (C) the questions are 
formulated which are aimed to be answered in this thesis. 
I.A.: THE SUPPRESSIVE EFFECT OF GLUCOCORTICO!DS ON THE HYPOTHA-
LAMO-PITUITARY-ADRENAL AXIS 
In 1952 Fraser et al. (!)reported a case of post-operative irreversible shock in 
a patient who had used glucocorticoids for a long time. From that moment on 
several reports appeared in which post-operative shock and subsequent death 
were attributed to adrenocortical insufficiency due to long-term glucocorticoid 
therapy (2-8, 19). 
Some patients with circulatory failure appeared to respond to parenteral 
glucocorticoid administration, which made it probable that there was a direct 
relation between shock and plasma corticosteroid levels. In 1961 Sampson et 
al. (9) confirmed this probability by the finding of low plasma cortisol levels in 
a patient with adrenal insufficiency which developed after stopping long-term 
glucocorticoid therapy. The number of carefully documented patients reported 
in the literature is rather small (9, 10, 11). The clinical symptoms to make the 
diagnosis of adrenocortical failure certainly are unreliable. As evidence for 
adrenocortical insufficiency Salassa et al. (3) found a striking reduction in the 
mean adrenal weight in a post-mortem study of patients who had received 
corticosteroids until the day of their death. A group of patients who died of 
similar causes, but did not receive glucocorticoids, had no signs of adrenal 
atrophy. In this study the reduction of adrenal weight was already found after 
treatment with glucocorticoids for 5 days. 
Later studies demonstrated that the return of the adrenal weight to normal 
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after stopping glucocorticoid therapy does not necessarily mean functional 
recovery of the HPA-axis (Axelrod, 19). 
Because it is impossible to prove in vivo the presence of an anatomic adreno· 
cortical atrophy, the functional integrity of the HP A-axis is studied by measuring 
HPA-responsiveness to a variety of provocative tests. The reaction to the stress 
of an insulin-induced hypoglycemia, to the administration of metyrapone, 
lysine vasopressin or ACTH are wellknown tests, to examine the reactivity 
of the HPA-axis (141). Each test has a different mode of action: insulin-
induced hypoglycemia acts at hypothalamic or higher brain levels, thus stimul-
ating the release of CRF and consequently of ACTH and cortisol (12). Metyra-
pone blocks the conversion of desoxycortisol to cortisol in the adrenal 
cortex by inhibition of the enzyme 11/l-hydroxylase. The decrease of plasma 
cortisol levels results in a compensatory increase in ACTH secretion which 
stimulates steroid production (13, 18). Eventually increased adrenal secretion 
of desoxycortisol is accomplished. Lysine vasopressin will stimulate directly 
the release of ACTH from the anterior lobe of the pituitary, and thus will 
cause a sharp increase in plasma cortisol concentrations. So, its mode of action 
is different from that of the insulin-induced hypoglycemia. This stimulation 
test of ACTH release was described by Webb-Peploe et al. {!42)to distinguish 
various causes of Cushing's syndrome, but can also be used to investigate the 
integrity of the HPA-axis after the use of glucocorticoids (141 ). Administration 
of synthetic ACTH 1 _ 24 results in a maximal stimulation of cortisol secretion, 
but only adrenocortical reserve is tested without supplying information on 
the functional activity of the hypothala.mo-pituitary part of the HP A-axis (14). 
ln the clinical setting of a patient taking glucocorticoids it is important to 
have information on the following points: 
I) how long does it take for glucocorticoids to induce a suppression of the 
HPA-axis? 
2) how long does it take before the HPA-axis is fully recovered after a period 
of exposure to glucocorticoids? 
3) which mechanisms play a role in the recovery of the HPA-axis? 
l.A.l. Time interval of suppression oft he HPA-a:x:is 
lt is difficult to determine exactly from the literature how fast glucocorticoids 
induce suppression of the HP A· axis. The main reasons are that various inw 
vestigators have been using different methods in evaluating HPA-integrity, 
while a wide range in dosage and duration of treatment with glucocorticoids 
in different patient groups makes a comparison of the results difficult. 
Christy et a!. (15) showed a decreased adrenal response to ACTH infusion 
in six patients who had been treated for 5-13 days with prednisone (20-30 mg 
daily). Plager et a!. (16) demonstrated an impaired reaction to the administration 
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of ACTH and metyrapone in four patients who had received cortisol 100 mg 
daily for only three days. Recently Streck et al. (17) have studied the effects 
on HPA function of high dose corticosteroid therapy (prednisone 30 mg/day) 
during 5 days. They used insulin-induced hypoglycemia and ACTH infusion 
as provocative tests. These authors found a significant suppression of HP A 
activity with both tests as measured for 2 days after prednisone administration, 
suggesting an impaired ACTH secretion and an insufficient adrenal reserve. 
Five days after concluding steroid therapy the cortisol response to hypoglycemia 
had returned to pre-treatment levels, but surprisingly the cortisol response to 
ACTH remained impaired. Others (18-21) found an abnormal response to 
hypoglycemia, metyrapone or lysine vasopressin, while the reaction of plasma 
cortisol to ACTH was already normal. They suggest that the three tests men-
tioned first are more sensitive in evaluating the integrity of the complete 
HP A-axis than ACTH stimulation tests. 
The insufficiency of the HP A-axis is more outspoken when the duration 
of glucocorticoid administration has been longer. Moreover, a dose-dependent 
relationship exists, in which higher doses of glucocorticoids produce a more 
severe suppression, especially when the dose exceeds thai of the normal cortisol 
production, which varies between 15-30 mg a day. Axelrod (19) mentioned 
that replacement doses of glucocorticoids probably exert no important sup-
pressive effects on the HPA-axis, as long as the mode of administration mimicks 
the circadian rhythm of cortisol closely. Under these circumstances there is 
no need to fear for an insufficient reaction of the HP A-axis to the stress of 
general anesthesia and surgery. This concept was studied by Danowski et al. 
(20), who did not observe signs or symptoms of acute adrenal insufficiency in 
117 patients, who had been treated with low doses of glucocorticoids (cor-
tisol or its equivalent in a dose of less than 25 mg daily) and underwent in 
total 80 stressful diagnostic or therapeutic procedures, without supplemental 
coverag'i. with glucocorticoids. These patients had been treated with low doses 
of glucocorticoids for hirsutism, irregular menses, or infertility. 
Others reported on the effects of higher doses of glucocorticoids on the 
response to stimulation tests and during stressful periods. Jasani et al. (10, 21) 
reported on patients with rheumatoid arthritis, treated with doses of gluco-
corticoids equivalent to 20-60 mg cortisol/day (mean 32 mg) over a prolonged 
period (6 months-5 years). Suppression of the HPA-axis was most outspoken 
after the use of the highest doses of glucocorticoids (i.e. mean 60 mg cortisol). 
Furthermore, during a small "standard" operation (synovectomy of the knee), 
plasma cortisol levels were significantly more reduced in the patients who had 
received the highest doses of steroids, implicating a diminished HP A-response 
to stress. In parallel, blood pressure during operation was also statistically 
significantly lower after the highest doses of glucocorticoids. In this study a 
group of patients occurred with normal reaction to ACTH stimulation, but an 
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insufficient response to metyrapone, and to insulin-induced hypoglycemia. 
This seems to underline further that an increase of cortisol in response to high 
concentrations of ACTH represents a maximal reaction of the adrenal cortex, 
but not necessarily normal functioning of the entire HP A-axis. On the other 
hand, a normal reaction of cortisol to metyrapone and to insulin-induced 
hypoglycemia suggests intact dynamic functioning of the HPA-axis, and in 
this category of patients no hypotension was observed during surgery (10, 
19, 21). 
I.A.2. Time course of the recovery of the HPA-axis 
When reviewing the literature, no certainty exists on the precise duration of 
the recovery of the HPA-system after various periods of administration of 
pharmacological doses of glucocorticoids. The potency of the HP A system 
to recover completely remains intact, regardless of the duration of the exposure 
to and the amount of glucocorticoids used, if the dosage of drugs is tapered down 
gradually and slowly enough. In general, one may say that the level of the dose 
and the duration of administration of steroids determine the speed of the 
recovery of the HP A-axis. In the studies of Streck and al. (17) mentioned al-
ready, recovery of the HPA-axis took 5 days after cessation of a ten day pred-
rrisone schedule, as assessed with an ACTH stimulationtest and the reaction to 
insulin-induced hypoglycemia. This is one of the first studies in which HP A 
suppression and its recovery after short·term steroid administration were 
properly documented. 
The classical study by Graber et al. (22) may serve to demonstrate the 
sequence of events after prolonged HPA suppression due to endogenous and 
exogenous hypercortisolism. 
They studied 8 patients with Cushing's syndrome due to an autonomous 
adrenocortical tumor, and 6 patients treated for 1-10 years with pharma-
cological doses of glucocorticoids. Thus, high circulating cortisol concen-
trations were present in both patient groups, and ACTH levels were sup-
pressed. After correction of hypercortisolism (removal of the adrenal tumor or 
discontinuation of the administration of exogenous steroids) they serially 
measured plasma cortisol and ACTH at 06.00 hr repeatedly for 12 months 
(Fig. l-1 ). In the first month after the correction of hypercortisolism plasma 
cortisol and plasma ACTH levels were subnormal, indicating suppression of 
hypothalamo-pituitary activity and of adrenocortical hormone secretion. 
Thereafter, in the second till third month plasma ACTH levels began to rise, 
but cortisol levels remained subnormal. From the third till the fifth month 
plasma ACTH levels became actually elevated in most patients, although 
plasma cortisol levels remained persistently lowered. Only 6 months after 
correction of hypercortisolism plasma cortisol levels began to rise under the 
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Fig. l-1. Recovery from prolonged pituitary-adrenal suppression (Graber 1967). 
influence of the continuously elevated ACTH levels. Finally, after 8-9 months 
ACTH and cortisol levels returned within the normal range, 
From this important study the following conclusions can be drawn: 
I) during the recovery of prolonged suppression oft he HPA-axis hypothalamo-
pituitary function is restored before adrenocortical function 
2) the recovery of pituitary function takes 1~2 months, while the recovery of 
the adrenocortical function takes much longer 
3) the recovery of basal hormone secretion by the complete HP A-axis after 
periods of suppression for longer than a year, requires at least 9~12 months, 
Confirming these results Livanou et al. (23) found a gradual normalization of 
plasma cortisol levels stimulated by insulin-induced hypoglycemia over a time 
course of one year in patients after withdrawal of prolonged glucocorticoid 
treatment. Furthermore, another report showed an even more protracted 
recovery of the HPA-system taking up to two years after removal of adreno-
cortical tumors (24). Axelrod (19) concludes that the possibility of the oc-
currence of adrenal insufficiency should be kept in mind in patients under-
going any stressful procedure up to one year after withdrawal of glucocorti-
coids given for periods longer than I to 4 weeks, 
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I.A.3. Mechanisms playing a role in the recovery of the HPA-axis 
Some controversy exists on the mode and site of action of glucocorticoids in 
suppressing ACTH release (25). The inhibitory effects of glucocorticoids on the 
functional activity of the HPA-system have been studied extensively in animal 
studies (26, 27, 27a, 28, 29, 30). In these studies the relationship between 
plasma and pituitary ACTH levels and the plasma concentrations of corti-
costerone were examined in non~stressed animals. An inverse relationship 
between ACTH and corticosterone levels has been reported in animals after 
exposure to corticosterone, and/or adrenalectomy. Thus, the concentration of 
plasma corticosterone seems to control the activity of the hypothalamo· 
pituitary system by regulating hypothalamic CRF activity and pituitary ACTH 
synthesis and release (31-34). There is evidence for the presence of gluco-
corticoid receptors in the anterior pituitary lobe, in the hypothalamus and in 
other higher brain centres via which glucocorticoids might exert their sup-
pressive actions on the HP A-axis. Buckingham (28) commented on findings 
which possibly indicated that glucocorticoids exert a negative feedback effect 
via higher brain centres, e.g. extrahypothalamic sites, like areas of the amyg-
daloid bodies and the hippocampus (41). 
Experiments in vitro have given ample evidencefor the existence of function-
ally active glucocorticoid receptors in the hypothalamus (31, 37, 38, 39). 
In other studies (35, 36) it appeared that the hypothalamic release of CRF 
and of CRF induced ACTH release was inhibited after glucocorticoid ad-
ministration in vivo. The synthesis of ACTH itself seemed not to be inhibited 
however. 
Stores of CRF in the median eminence of the hypothalamus are increased in 
adrenalectomized rats, but glucocorticoids prevent under those circumstances 
the release of CRF (40). Experiments on the effects of the administration of 
glucocorticoids on the regulation of ACTH under stressful conditions show a 
marked suppressing effect of high levels of circulating glucocorticoids on the 
stress responsiveness of the HPA-axis (41). 
At present, the concept of a delayed or proportional feedback mechanism 
of glucocorticoid hormone controlling the release of ACTH in response to 
stressful stimuli is accepted. Sayers et al. (42) demonstrated the stimulatory 
effects of stressful stimuli on the HPA-system and subsequent inhibition of 
these effects induced by glucocorticoids. From this work and the work of 
Dallman et al. (43) it was concluded that there is a delay of about 2 hours, 
before there is a clear inhibition by glucocorticoids on stress responsiveness. 
However, Smelik (44) found no direct influence of single large doses of corti-
costerone on the responsiveness of the HPA-axis; only after normalization of 
circulating glucocorticoid levels there was evidence of inhibition of ACTH 
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release somewhat later. Others (Buckingham et al. (30 ); Hodges et al. (45)) 
have confirmed these negative observations. 
There is also evidence for the existence of a rapid feedback system in the 
inhibition of stress-induced HPA activity. Dallman et al. (43) and Jones et al. 
( 47) demonstrated that inhibition of ACTH secretion in response to stress 
occurred within a few minutes after the infusion of glucocorticoids. Jones et 
al. (47) have shown that this rapid feedback mechanism is dependent on the 
rate of increase of plasma corticosterone levels, but others have criticised the 
physiological significance of these findings (28). ACTH secretion was measured 
indirectly, anesthesia with barbiturates was used, and the rate of steroid-
infusion was high (Buckingham; 28). In other studies the existence of a rapid 
feedback mechanism was confirmed and different receptors were demonstrated 
for rapid and delayed feedback actions of glucocorticoids (48). 
Summarizing these results Gann et al. (46) suggest that the corticosterone-
induced inhibition of CRF secretion is mediated mainly by the fast· rate-
sensitive mechanism, but that the synthesis of CRF is controlled by the delayed 
level-sensitive system ( 49). However, modulation by glucocorticoids of CRF 
synthesis and secretion is evidently more complex. Some studies showed that 
both delayed- and rapid-rate-sensitive feedback mechanisms may inhibit CRF 
synthesis and secretion acting at sites remote from the CRF neuron (SO). 
There is a distinct variety in the changes in responses to different stimuli in-
duced by glucocorticoids. Some are inhibited by large doses of steroids, where-
as the responses to other stimuli are suppressed at low stimulus intensity, but 
not at high intensity ( 46). The possibility of the existence of multiple path-
ways to the CRF neuron was raised: low threshold, steroid suppressible path-
ways as well as high threshold, non-steroid suppressible pathways to the 
hypothalamus would offer an explanation for these conflicting findings (5). 
Having demonstrated the different sites at which glucocorticoids may 
exert their inhibitory actions under various conditions, it remains difficult 
to ascertain the relative importance of those different feedback sites under 
normal physiological conditions. From the available evidence, Buckingham 
(28) reasons that glucocorticoids exert their actions on stress-induced ACTH 
activity predominantly at hypothalamic centres, or even at higher brain cen-
tres, whereas ACTH secretion under basal non~stress conditions may be con· 
trolled via anterior pituitary lobe receptors. N, shown by Hillliouse and Jones 
(52) and Yasuda and Greer (53), changes in the levels of circulating gluco-
corticoids influence pituitary ACTH secretion more readily than the CRF 
content of the hypothalamus. On the other hand, the suppressive action of 
corticosterone per se seems to be more pronounced at the hypothalamic level 
than at the level of the anterior pituitary gland (33, 39). 
Influences of adrenocortical hormones, other than cortisol and corti-
costerone on HP A activity have been investigated by Jones and Hillhouse 
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(54). They suggested that due to differences in structure-activity relationships, 
both the 11/l·OH and the 210-0H groups of the adrenocortical steroids are 
essential for the fast-rate-sensitive feedback mechanism. Aldosterone does 
not seem to have an important inhibitory action on HPA·activity as may be 
concluded from observations on patients with primary hyperaldosteronism, 
although at high aldosterone concentrations inhibition of CRF secretion in 
rat hypothalami in vitro was observed (32). 
I. B. CORTICOTROPIN RELEASING FACTOR 
I.B.l. Nature and regulation ofCRF 
De Groot and Harris (55) were the first to demonstrate in 1950 an influence 
of the hypothalamus on the pituitary-adrenal system. In elegant experiments 
they implanted in rabbits an electrode in the hypothalamus, which was con· 
nected with a coil inserted between skull and scalp. The outer tum of the coil 
was connected to an indifferent electrode. By placing the rabbits head in an 
electromagnetic field they could induce a voltage in the coil and subsequently 
involve stimulation of the hypothalamus. Electrical stimulation of certain 
areas of the hypothalamus generated a remarkable increase in activity of the 
adrenal cortex. They postulated from these experiments that a humoral factor 
from nerve endings of the hypothalamus was released into the hypophyseal 
portal vessels, which appeared to stimulate ACTH release. Saffran et a!. named 
this humoral substance in 1955: corticotropin releasing factor (CRF) (56). 
After successful experiments to extract substances with CRF activity from 
hypothalamic tissue in the years that followed many investigators attempted 
to elucidate the exact chemical identity of CRF, but it remained a mystery 
until very recently. 
Porter et a!. showed that extracts of blood from the capillaries of the 
hypophyseal portal vessels from hypophysectomized, stressed dogs caused an 
increased activity of the adrenal cortex in cortisol treated rats, thus providing 
further evidence of a hypothalamic CRF (57, 58). In vivo studies in rats and 
other animals demonstrated that crude extracts of hypothalami activated 
ACTH release also in the presence of sections through the hypothalamus or in 
corticosteroid treated animals (59, 60). 
The exact chemical nature of CRF remained unknown until very recently. It 
became evident from extraction and purification studies that CRF is a poly-
peptide, since proteolytic enzymes like trypsin or pepsin were able to destroy 
CRF-like activity in hypothalamic extracts. Moreover, subsequent studies 
showed the existence of 2 fractions with CRF-like activity: C<· and~- CRF, and 
a resemblance with vasopressin was noted (61, 62). 
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It was thought for some time that vasopressin might be identical with CRF. 
For instance in rats with diabetes insipidus induced by hypothalamic lesions 
the degree of inhibition of the HPA system appeared to have a proportional 
relationship with the degree of diabetes insipidus (63). Recent reports found a 
comparable elevation of the content of immunoreactive vasopressin and of 
CRF in adrenalectomized rats (64). After administration of glucocorticoids to 
adrenalectomized rats both the expected elevation of the CRF and the vaso-
pressin content were prevented (64, 65). 
In 1979 Gillies and Lowry (66) proposed that CRF might be a complex 
system, in which vasopressin is a major component which is modulated by 
other factors with weaker CRF activity. Using a CRF bioassay, chromato-
graphy and immunological techniques they found vasopressin-like material in the 
rat stalk median eminence to be identical to synthetic arginine vasopressin, but 
having only 30% of the biological activity of the extract. They suggested that 
this lack of full bioactivity of the major CRF peak, containing "arginine vaso-
pressin-CRF" (A VP-CRF), was caused by removal of some synergistic factors. 
After stabilization of the chromatographic column with ascorbic acid, fractions 
from other areas in the chromatogram were recombined with the "AVP-CRF" 
complex, giving a synergistic effect. Other fractions did not have a significant 
bioactivity, measured by CRF bioassay. The combinations of added factors and 
"AVP-CRF", but also those factors with synthetic arginine vasopressin shared 
dose-response characteristics, identical to that of crude stalk median eminence. 
They concluded that the loss of bioactivity of this multifactorial system by 
separation techniques, which is caused by its instability under non-reducing 
conditions, is an important reason for the failure to characterize CRF. 
Zimmerman et al. (67) found evidence in monkeys for the existence of a 
specific axonal pathway for vasopressin directly to the hypophyseal portal 
system. This pathway originated in the paraventricular nucleus of the median 
eminence of the hypothalamus. Glucocorticoids appeared to exert an in-
hibitory influence on this pathway. They also speculated that vasopressin 
might be either a CRF-like substance or an assistant of CRF. 
On the other hand, there was as much, or even more convincing evidence 
that vasopressin is not identical to CRF in the rat. For instance: pentobarbitone/ 
morphine was able to block the ACTH releasing effect of vasopressin (68). De 
Wied eta!. (69) demonstrated the absence of pressor activity in hypothalami of 
hypophysectomized rats, in which CRF activity was present. In addition 
McDonald et a!. (70) did not find a correlation between the pressor and CRF 
activity of hypothalami in response to stimuli as water deprivation, water 
loading or rticotine administration. It is important to mention that experiments 
with Brattleboro rats (rats with inherited diabetes insipidus) have shown a 
diminished activity of the hypothalamo-pituitary-adrenal system. But, median 
eminences or hypothalamic extracts from these rats still possess CRF bio-
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activity, and these animals retain the ability to react to stress with a rise of 
circulating corticosterone concentrations (71, 72, 73, 7 4). In addition, in other 
observations Buckingham et al. made it clear that there had to be a difference in 
chemical structure between vasopressin and CRF from hypothalamic extracts 
{75). Those results are in contrast with the studies of Gillies et al. (66) men-
tioned above. Possibly, the methods used to demonstrate the CRF bioaclivity, 
i.e. isolated pituitary cells vs. pituitary segments, varied in so many aspects, 
that important differences in the results were to be expected. 
Only very recently, Vale et al. (76) reported the characterization of a poly-
peptide from ovine hypothalamic tissue, which was able to stimulate directly the 
secretion of ACTH. After ultrafiltration and chromatography, two zones with 
ACTH releasing activity were detected. The first zone had a higher intrinsic 
activity than the second, which on subsequent purification appeared to be 
arginine vasopressin. The zone with the highest ACTH releasing activity was 
further analysed by ion exchange chromatography and high pressure liquid chro-
matography. The primary structure of the major component was identified to 
be a polypeptide with 41 amino acids. 
After synthesizing CRF, these authors demonstrated that synthetic CRF 1 _ 41 
was identical to the purified native CRF, and both were highly active in stimul-
ating ACTH secretion in vitro and in vivo. Incubation of cultured pituitary 
cells with dexamethasone, prior to CRF administration, demonstrated a dose-
dependent inhibition of ACTH release. They concluded that the high potency 
and intrinsic activity to stimulate ACTH secretion in vitro and in vivo and its 
presence in the hypothalamus indicated that this peptide actually was CRF. 
I.B.2. Regulation of the secretion of CRF 
In the last years many studies have been carried out on the control mechanisms, 
which regulate the secretion of CRF. Selye (77) was the first to find ACTH 
mediated effects on the adrenals produced after diverse stressful stimuli. 
Today, CRF is known to be one of the most important factors in regulating 
ACTH activity. The CRF content of the hypothalamus rises in accordance 
with, or just prior to increases in pituitary and plasma ACTH levels. Exposure 
of rats to ether stress results in an initial fall of the hypothalamic CRF con-
tent, followed by a sharp rise, which is directly followed by an increase of 
pituitary ACTH content and of ACTH release into the circulation and sub-
sequently rising plasma corticosterone concentrations (31 ). likewise, adrenal-
ectomy causes an exaggerated response to stress, parallel to the increase of 
ACTH. On the other hand, administration of glucocorticoids reduced CRF and 
ACTH activity in a similar way (28, 31). 
A prominent feature of the HPA-axis is the existence of a circadian rhythm. 
Probably, this is of great importance in maintaining vital metabolic processes 
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at adequate levels, with equally adequate concentrations of glucocorticoids, thus 
preventing overshoot (46, 79). The rhythm is conditioned by alight -dark cycle, 
and may be influenced by the time of food intake in some species, although 
probably not in man (80, 81, 82). 
The pacemaker of the circadian rhythm lies in the neurons of the supra-
chiasmatic nucleus (83): lesions in this particular area destroy the rhyth-
micity (84). It is also clear from anatomical studies that the supra-chiasmatic 
nucleus of the hypothalamus is stimulated by light stimuli mediated through 
the retina-hypothalamic tract. The ventromedial nucleus has to be intact, to 
entrain the circadian rhythmicity by feeding (85). 
There are probably two mechanisms regulating the interaction between the 
circadian rhythmicity and the response to stressful stimuli. First, the efficacy 
of glucocorticoids to suppress ACTH in man and rat appears to be greatest 
when the concentrations of circulating glucocorticoids are the lowest (86). 
Secondly, serotonin (5-hydroxytryptamine) has a marked influence on circadian 
rhythmicity in adrenalectomized rats. It exerts a more profound stimulation 
of ACTH secretion when applied in the morning than in the evening. To ex-
plain these mechanisms, there has to be an independency from circulating 
glucocorticoid levels (87, 88). On the other hand the hypothalamic content of 
CRF is higher in the evening than in the morning, and there is clearly no direct 
correlation between the CRF content, and the tendency to secrete CRF in this 
situation (88). Krieger and Rizzo (89), and Vernikos-Danellis et a!. (90) de-
monstrated a dependence of the circadian rhythmicity of corticosterone on 
serotonin. They found that blockade of serotonin synthesis prevented the 
circadian rhythmicity and a consequent rise in plasma glucocorticoids. How-
ever, the response to stress was not prevented, and even enhanced. 
I.B.3. Effects of ACTH on CRF: an internal "short" loop feedback? 
The negative feedback that glucocorticoids exert on the HP A-axis has been 
demonstrated conclusively, but some studies in the sixties and early seventies 
raised the possibility that circulating plasma ACTH levels might also directly 
influence CRF secretion and subsequent ACTH release from the anterior 
pituitary. 
Gemzell and Heijkenskj6ld (91) and Kitay et a!. (92) found that the ad-
ministration of ACTH reduced the anterior pituitary weight and the anterior 
pituitary ACTH content in adrenalectomized rats. They suggested that the 
secretion of ACTH is regulated not only by circulating glucocorticoid levels, 
but also by the circulating plasma ACTH levels: the existence of a "short" 
loop feedback mechanism was postulated. Hodges and Vernikos found a 
greater increase in plasma ACTH levels in adrenalectomized rats submitted to 
stress when the initial blood levels of ACTH were low, than when they were 
high (93). 
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Attempts to elucidate the mechanisms involved were made by Halasz and 
Szentagothai who implanted anterior pituitary tissue in the infundibular recess 
of the third ventricle of rats and found a suppression of adrenal function in the 
presence of such implants (94). Motta et al. (95) implanted cannulae bearing 
solid ACTH in the median eminence, frontal cerebral cortex and pituitary 
gland with stereotactic procedures. The rats were submitted to constant mild 
environmental stress. The results showed the ACTH implants in the median 
eminence to be effective in reducing significantly circulating corticosterone 
levels and anterior pituitary weight. They found no effects however of implants 
in the cerebral cortex or in the pituitary gland. Motta et a!. explained these 
results as evidence for the existence of a "short" loop negative feedback 
mechanism of ACTH secretion, and supposed that the stalk median eminence 
contained receptors, responding to ACTH (96). It is noteworthy that the rats 
serving as controls in the experiments of Motta et a!., had very high circulating 
corticosterone levels, probably due to the constant environmental stress. The 
same authors demonstrated that treatment of adrenalectomized-hypophysec-
tomized rats with ACTH reduced the CRF content of the hypothalamus to the 
levels found in rats, which were only adrenalectomized, and postulated CRF 
activity to be regulated both by glucocorticoids and ACTH (97). 
Using a pituitary incubation method to measure hypothalamic CRF bio-
activity Seiden and Bradish (98) investigated the effects of adrenalectomy or 
hypophysectomy or both together on hypothalamic CRF activity. The results 
of their experiments indicated that there was in fact a "short" loop system in 
which ACTH influenced hypothalamic CRF activity: they found in all different 
conditions studied, an inverse relationship between the plasma level of ACTH 
and CRF activity. After injection of synthetic ACTH (2 U, s.c., 4 times daily 
for l week) adrenalectomized-hypophysectomized rats were shown to have 
a substantially lowered hypothalamic CRF activity when compared with 
adrenalectomized*hypophysectomized controls receiving saline injections. On 
the other hand they found no elevation of CRF activity shortly after adrenal-
ectomy (5 or 7 days), as described by Motta eta!. (97). The authors concluded 
that a role of plasma ACTH in regulating CRF activity might be important, but 
that the actions of adrenal glucocorticoids are probably of much more im-
portance. 
One of the few studies investigating a possible "short" loop feedback 
phenomenon in man was carried out by Upton et a!. (99). In patients with 
lipoatrophic diabetes (Seip-I.aurence syndrome), a rare genetically determined 
disease characterized by lipodystrophy, diabetes mellitus, hyperlipemia, 
hepatic insufficiency and chronic hypersecretion of CRF and LHRH (JOO), 
ACTH was administered and plasma CRF bioactivity was determined; the latter 
was shown to decrease in response to ACTH in 3 of 4 patients. Moreover, 
remarkably the cortisol levels throughout the day were high (24 to 35 11g/ 
!3 
I 00 ml), without an increase after the administration of high doses of ACTH. 
The conclusions of Upton et al. on a possible direct "short" loop feedback 
effect of ACTH were based on these data in particular. No measurement of 
plasma ACTH levels in basal conditions were carried out, and the specificity 
of the method of plasma CRF assay is difficult to judge. 
Takebe et al. (101) found that CRF bioactivity in the median eminence 
was suppressed after ACTH administration for 5 days to adrenalectomized-
hypophysectomized rats under ether stress, but not under ether laparotomy 
stress with intestinal traction, indicating a possible hierarchy in different stress 
mechanisms. 
Fehm et al. (102) found no evidence for the existence of an "ultra-short" 
feedback mechanism by the addition of ACTH to the medium of incubated 
pituitary cells in an attempt to inhibit ACTH release from the dispersed pituitary 
cells. 
In summary, there are several well documented studies, presenting evidence 
for the existence of a "short" loop negative feedback mechanism in which 
plasma ACTH levels may inhibit CRF secretion at the hypothalamic level. On 
the other hand, almost all these data have been obtained in stressed adrenal-
ectomized and/or hypophysectomized rats, and the importance of the reported 
phenomenon under physiological conditions has yet to be shown. 
l.B.4. Neurotransmitters and CRF secretion 
The mechanisms which control the secretion of CRF have been examined by 
many investigators with many different methods. 
It has been demonstrated that excitatory and inhibitory pathways origin-
ating from specific areas in the hypothalamus, the amygdalic bodies, the 
hippocampus, but possibly also in the thalamus, the basal septal area, and 
parts of the reticular formation are involved in the regulation of CRF release 
(103, 104, 105). One of the problems in interpreting these results was that the 
use of in vivo techniques in which drugs are administered intraventricularly, 
or directly implanted into certain brain areas, does not necessarily result in 
specific data. For instance, drugs may diffuse to other areas, the stress of 
implantation may influence the outcome, interactions of the drugs with different 
receptors may occur after drug administration, with different results (28). 
The use of an in vitro method in the study of CRF release, in which whole 
rat hypothalami are incubated with different putative neurotransmitters, made 
it more easy to demonstrate inhibitory or excitatory effects of different 
neurotransmitters, thus also determining the site of action of those substances. 
However, one should bear in mind that results of in vitro studies might not be 
representative for the in vivo situation. 
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l.B.4a. Stimulatory influences on CRF release 
The importance of a cholinergic pathway in the control of CRF has been 
demonstrated convincingly by several authors. Endr6czi et a!. were the first 
to implicate acetylcholine as putative neurotransmitter: they showed that the 
activity of the hypothalamo-pituitary-adrenal system was stimulated by im-
plantation of carbachol in different brain areas {106). Others confirmed this 
observation (107, !08, 109, 110, Ill). Jones et al. (54) investigated in vitro 
the stimulation of the secretion of CRF from both hypothalamus and median 
eminence, after Incubation with acetylcholine at different concentrations. A 
dose-dependent stimulation of the release of CRF from the hypothalamus was 
found with acetylcholine concentrations ranging from 1-5 pg/ml. Incubation 
of acetylcholine with tissue of the median eminence did not cause a release of 
CRF, even at high doses. In the presence of 10 ng norepinephrine, CRF release 
at concentrations of 3 pg/ml acetylcholine was significantly less, but again a 
dose dependent rise tn CRF release was noted at higher concentrations. No 
effects of acetylcholine on CRF secretion were noted from hypothalamic 
tissue containing the ventromedial, dorsomedial and paraventricular nuclei 
(54). Both the synthesis and release of CRF are stimulated by acetylcholine 
(112, 113, 114, 122). The actions of acetylcholine on CRF secretion are 
probably mediated by nicotinic and muscarinic cholinergic receptors. Jones 
et al. stated that the mediation is predominantly nicotinic, because only hexa-
methonium, and not atropine, fully antagonizes the acetylcholine mediated 
release of CRF (54). In contrast with these results are those of Buckingham 
who found total inhibition of acetylcholine induced CRF release only by a 
combination of specific nicotinic and muscarinic receptor antagonists (112). 
More controversy exists concerning the role of serotonin. Fuller (115) 
recently reviewed the evidence from in vitro and in vivo studies that sero-
tonergic neurons stimulate the release of CRF from the hypothalamus. For 
some time there was considerable uncertainty whether the influence of sero-
tonin on CRF and ACTH activity was excitatory or inhibitory. Implantation 
of serotonin tn vivo either into the lateral ventricles, or into hypothalamic 
areas had no effect on basal CRF secretion, but inhibited the response to ether 
stress and surgical stress (116, 117). Others seemed to support these findings 
(90, 118). 
Krieger and Rizzo (89) were the first to suggest that serotonin might have 
a stimulatory effect on CRF production and release. More recently it was 
shown that serotonin in vitro at concentrations ranging from 0.1 to 10 ng/ml 
stimulated CRF release tn a dose dependent manner (54). Cyproheptadine, a 
relatively non-specific serotonin antagonist, and methysergide antagonized 
these effects (54). 
Local application of serotonin to certain brain areas as the ventral hippo-
campus and the reticular formation resulted in an acute rise of plasma gluco-
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corticoids in guinea pigs (119), whereas Krieger and Krieger observed an 
elevation of glucocorticoids after serotonin implantation directly in cat brain 
(109). In man and rhesus monkeys infusion of 5-hydroxytryptophan (5-HTP), 
a precursor of serotonin, significantly elevated the circulating glucocorticoid 
concentrations (120, 121 ). However, it became clear from the studies of 
Vermes and Telegdy (116, 117), that in vivo experiments in rats involving 
intracerebral administration of serotonin did not induce directly an excitatory 
response of the pituitary-adrenal system to this neurotransmitter. The existence 
of a cholinergic interneuron as mediator of serotonin~induced CRF release 
was suggested by Jones et al. (54), because they found an inhibition of the 
stimulating effect of serotonin by hexamethonium and atropine. 
Pharmacological in vivo studies involving various agents further elucidated 
the enhancing effect of serotonin on HPA activity. Those agents consisted 
of several groups: 1) serotonin precursors like 5-HTP; 2) direct serotonin 
receptor agonists like quipazine and L- (m- chlorophenyl)-piperazine; 3) serotonin 
re-uptake inhibitors like fluoxetine, zimelidine, and certain tricyclic anti-
depressants (123); 4) serotonin releasers like p-chloroamfetamine, fenfluramine 
and norfenfluramine (115). The elevation of plasma corticosterone levels in 
rats by the serotonin precursor 5-HTP is stereospecific, and is potentiated by 
monoamine oxidase inhibitors. Additional evidence of serotonin as a particular 
mediator of CRF release, is greatly strengthened by the stimulation of this 
release by fluoxetine, a serotonin re-uptake inhibitor (124). The serotonin 
receptors involved in the S-HIP-induced elevation of CRF may become super-
sensitive, as shown by Kawa et al. (125) and Clemens et al. (126). Kawa 
described augmentation of 5-HTP induced CRF release by pretreatment with 
5,6-dihydroxytryptamine intraventricularly, while Clemens found an enhance-
ment of 5-HTP-induced CRF release after feeding rats a tryptophan free diet. 
Of the direct serotonin receptor agonists quipazine has been studied most 
extensively; it caused a dose~ dependent increase in plasma corticosterone levels 
in rats, which was not influenced by fluoxetine pretreatment, indicating a 
direct serotonin receptor stimulation (127). 
Fluoxetine has a maximal stimulating effect on CRF release within l-4 
hours (128). 
As described by Lahti and Barshun (123) and Sigg et al. (129) certain 
tricyclic antidepressants may act as specific serotonin re-uptake inhibitors, and 
elevate plasma corticosterone levels. Especially imipramine and chlorimipramine 
cause such elevations. 
Fenfluramine is a serotonin-releasing compound used clinically as an anorectic 
drug. It also elevates CRF-induced corticosterone levels (115). By depleting 
serotonin concentrations in the brain the excitatory effect of fenfluramine can 
be antagonized (115). 
p-Chlorophenylalanine is a potent serotonin-depleting drug, which is able to 
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antagonize CRF release. It is therefore used in testing a possibly serotonergic 
pathway (130). p-Chlorophenylalanine is able to prevent the stimulating effects 
of p-chloroamphetamine, a serotonin releasing drug (130). 
l.B.4b. Inhibitory influences on CRF release 
The hypothalamic secretion of CRF is inhibited by catecholamines and by 
monoamines, in which group 'Y-aminobutyric acid (GABA) has a predominant 
place. 
Ganong et a!. performed many studies on the role of catecholamines in re-
gulating the secretion of CRF (131 ). They found an inhibition of stress-
induced ACTH secretion in dogs by the catecholamine precursor lrdopa and 
by drugs that release catecholamines (132). It became likely from their ex-
periments that L-dopa had to be transformed in order to be able to inhibit 
ACTH secretion (133, 134). Dopamine does not seem to play an important 
role, since dopamine-receptor stimulating drugs like apomorphine do not have 
a clear effect on ACTH secretion (134), although initial studies reported an 
inhibitory effect of dopamine when implanted intraventricularly (135). Nore-
pinephrine had a clear inhibitory influence on ACTH secretion after intra-
ventricular administration {134). Hillhouse et a!. (! 14) and Jones et a!. (54) 
found a dose-dependent reduction of CRF release in response to acetylcholine, 
when norepinephrine was administered in doses of 3-10 ng/ml. This inhibition 
by norepinephrine was abolished by phentolamine, a specific a-adrenoceptor 
antagonist. Others confirmed this, and found propranolol, a ~-adrenoceptor 
antagonist, to be effective to prevent a norepinephrine-induced inhibition of 
CRF release (136). Norepinephrine is able to inhibit acetylcholine- as well as 
serotonin-induced stimulation of CRF release (114). Epinephrine and a-
adrenoceptor agonists like phenylephrine and methoxamine produced a similar 
inhibitory effect on CRF secretion in vitro as norepinephrine (137). ln con-
clusion, all the available evidence points towards an a-adrenergic inhibitory 
pathway in the production and release of CRF. 
The effects of GABA on CRF release were investigated by Makara and Stark 
(138), Marvin du Pan and Gomez (139), and Jones et a!. (54). Infusion of 
GABA into the third ventricle of rats inhibited the response of the HP A-axis 
to surgical stress. GABA caused inhibition of CRF release in response to 
acetylcholine and serotonin in vitro in a dose-dependent way. GABA is present 
in high concentrations in the lateral preoptic region of the rat hypothalamus 
(54, 138, 139). An antagonist of GABA, picrotoxin, produced a significant rise 
in plasma corticosterone in rats, who were conscious at the time of the ex-
periments. Also, under anesthesia, picrotoxin caused a rise in circulating 
corticosterone concentrations (138). Picrotoxin prevented in vitro the inhibition 
of GABA (10 ng/ml) on the release of CRF in response to serotonin significant-
ly {54). Intraventricular injection of bicuculline, another GABA antagonist, 
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caused in vivo a rise in ACTH release. This was completely prevented by the 
simultaneous administration of GABA (54). In addition, Jones et al. (54) did 
not find interactions between the inhibitory effects of GABA and norepine-
phrine. The possibility of an auto-feedback effect of CRF on its own release, 
mediated by a GABA inhibitory neuron, was raised by the experiments of Yagi 
and Sawaki (! 40), who found that collaterals from parvicellular cells in the 
tuberoinfundibular region in the hypothalamus synapse with GABA inhibitory 
neurons. From all the studies mentioned above, it is clear that GABA exerts an 
inhibitory effect on CRF release. However, some doubt still exists on the 
presence of an auto-feedback of CRF, as mediated by the inhibitory GABA 
neuron. It is possible that there is a direct inhibition of CRF release by the 
GABA neuron, without a collateral axon of the CRF neuron. 
In sununary, Jones et al. proposed a model of the neurotransmitters, in-
volved in the release of CRF from the rat hypothalamus (54). The existence of 
a cholinergic interneuron, mediating the serotonin-induced CRF release is 
disputed by others (28, 12). Nevertheless, evidence accumulates that serotonin, 
possibly by influencing circadian rhythmicity, has a stimulating capacity on 
CRF release, as does acetylcholine. GABA-ergic and adrenergic pathways 
inhibit the production and release of CRF (Fig. 1-2). 
m=mz4 inhibitory neuron 
~ excitatory neuron 
SHT Lti 
=-=r'r '- GABA 
NA ~ 
CRF 
porta! capillary 
Fig. 1-2. Proposed model of neurotransmitter regulation in the release of CRF from 
hypothalamus (Jones; 1976). 
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I. C. QUESTIONS TO BE ANSWERED IN THIS STUDY 
l. How important is the hypothesized direct "short" loop negative feedback of 
ACTH on its own synthesis and release? Can the model of an ACTH secreting 
tumor-bearing rat be used to study the relationships between inhibitory and 
stimulatory effects on the hypothalamo-pituitary axis? 
2. Is it possible to stimulate the hypothalamo-pituitary axis by alterations in 
the putative hypothalamic neurotransmitter levels, even in the presence of 
high circulating glucocorticoid levels in the rat? 
3. Does suppression of the HP A-axis occur in man, even after short-term 
glucocorticoid administration? If so, how long takes its recovery? What 
effects can be observed on cortisol secretion during the stress of anesthesia 
and operation? 
4. Does simultaneous administration of glucocorticoids in combination with a 
substance with possible CRF stimulating properties, prevent the suppression 
of the hypothalamo-pituitary-adrenal axis in man? 
The results, which are presented in this thesis to answer the questions 
formulated, have been obtained in two different ways. 
ln chapter II the use of the model of the ACTH/PRL secreting transplantable 
tumor 7315a is described. In addition the possible direct "short" loop feed-
back effect of ACTH is studied in this model. 
In chapter Ill it is investigated whether the systemic administration of CRF-
stimulating drugs will be able to counteract the suppressive effects of gluco-
corticoids. 
The data, concerning questions 3 and 4, whether short-term glucocorticoid 
administration causes suppression of the HPA-axis in man and whether this 
suppression can be prevented, will be discussed in detail in chapter IV and V. 
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Chapter II 
The model of the transplantable ACTH-secreting 
pituitary tumor 7315a. No evidence for a direct 
"short" loop feedback of ACTH 
In this chapter we will describe the effects of a transplantable ACTH-secreting 
pituitary tumor on the HPA-axis. 
!I.A. METHODS 
ll.A.l. The transplantable ACTH and Prolactin secreting pituitary tumor 7315a 
The transplantable ACTH and prolactin (PRL) secreting pituitary tumor 7315a 
used in our experiments was obtained from Dr. R.M. MacLeod, Charlottesville, 
Virginia, USA. Female Buffalo rats with a body weight varying between 
150-250 g were inoculated subcutaneously on the back between the scapulae 
with a suspension of the tumor cells, as described earlier by MacLeod et a!. (I). 
The rats were housed five to six per cage under artificial light from 06.00 to 
21.00 h, and given free access to water and rat chow. After three to four 
weeks, when the tumors measured approximately 1.5 X 1.5 - 2 X 2 em 2 , the 
experiments were performed. The measurement of the tumor in centimeters 
squared has been shown to correlate significantly with tumor weight (2). The 
animals were killed by decapitation between 08.30 - 09.30 h. 
After decapitation the pituitary was quickly removed, and the anterior 
lobes were separated from the intermediate lobe. The anterior lobes were in-
cubated in 2 ml medium 199 (GibcoBio-cult) NaHC03 1.25 g/1. The flasks 
were incubated in a Dubnoff shaker at 37°C, in an atmosphere of 95% 0 2 / 
5% C02 , for 4 hours. After incubation the medium was removed, and the 
pituitary glands rinsed and homogenized in 2 ml distilled water, and acidified 
with I ml HCL (0.1 N). The ACTH content of the medium and the content of 
anterior lobe were measured using the bioassay as described below. All data 
are expressed as means ± S.E.M. Statistical analysis was done with analysis of 
variance. 
ll.A.2. Bioassay of ACTH 
We used a bioassay for the determination of the ACTH concentration, kindly 
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provided by Dr. G.H. Mulder (Amsterdam). The methodology and the cha-
racteristics of the bioassay have been described in detail in his thesis (3). 
In short the ACTH bioassay is performed as follows: twelve female Wistar 
rats, with a body weight of approximately 150-200 g are sacrificed by de-
capitation between 08.30 and 09.30 hour. The adrenals are removed, cleaned 
of adhering adipose tissue, and subsequently cut in pieces, until a suspension 
is obtained. This suspension is placed in a flask containing collagenase type l 
(Sigma) 30 mg in 10 ml Krebs-Ringer-bicarbonate-glucose buffer (KRBG 
buffer). The composition of 100 ml of this buffer is as follows: 80 ml distilled 
water, 10 ml Stock A (NaCl 119 mM, KCL 4.7 mM, MgS04 . 7H2 0 1.2 mM, 
CaCh. 2H2 0 2.5 mM, KH 2 P04 1.2 mM)and 10 ml Stock B (NaHC03 24.9 mM), 
and 0.209 g d-glucose {1!.6 mM). 
All the glass materials used have been siliconized. The suspension of adrenal 
tissue in the collagenase-KRBG buffer was incubated in a Dubnoff shaker 
for fifty minutes, under an atmosphere of 95% 0 2 /5% C02 , at 37°C. The 
dispersion, initiated by incubation in the collagenase containing buffer was 
completed by gently sucking up adrenal tissue pieces with a Pasteur pipet, 
and blowing them out. Usually about 50 pipet excursions sufficed to get 
almost total disruption of adrenal tissue parts. The cloudy suspension was 
centrifuged at 100 X g, during 10 minutes, at a temperature of 20°C; the 
speed of the centrifuge was accelerated very slowly, while at the end of the 
procedure no brakes were used. The pellet was resuspended in 10 ml KRBG 
with 0.5% bovine albumin. This suspension was filtered through a nylon 
cloth, with micropores of 60 pM, and was centrifuged again for 10 minutes 
at 100 X g. This pellet was resuspended in I ml KRBG buffer with 0.5% al-
bumin and then added, very carefully to 10 ml KRBG buffer with 2% al-
bumin. The tube was centrifuged 5 minutes at 10 X g. The final pellet was 
resuspended with 60-70 ml KRBG buffer, containing 0.5% albumin. Further-
more, 10 pi CaCI 2 . 2 H2 0 8.08% and 100 E TrasylolR (Bayer) perm! KRBG 
buffer were added to stabilize the suspension and antagonize the potentially 
deleterious effects of the collagenase. The cell suspension was pipetted into 
teflon incubation flasks, each flask already containing 0.1 ml sample and 
receiving I ml of prepared adrenal cell suspension. During the whole procedure, 
the cell suspension was kept in constant, gentle movement by mechanical 
stirring to ensure equal cell samples. 
The standard aliquots of synthetic ACTH 1 _ 24 (Organon) were added at the 
same time as the samples to be measured. When using the third International 
Standard, 10 pg ACTH 1 _ 24 equals I pU. The standard series of synthetic 
ACTH 1 _ 24 consisted always of the same range concentration: 
standard I = 6!5.38 pU/ml 
standard 2 = 307.69 11U/ml 
standard 3 = 153.85 11U/ml 
standard 4 = 61.54 pU/ml 
standard 5 = 30.77 pU/ml 
standard 6 15.38 pU/ml 
standard 7 = 6.15 pU/ml 
standard 8 3.07 pU/ml 
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This standard series was prepared in teflon tubes, containing saline 0.9% and 
albumin 0.5% at pH 3.5. Then, 0.1 ml of these concentrations was added to the 
incubation tubes. A sample containing only saline 0.9% and albumin was 
always included in the bioassay as a blank. All samples were measured in 
duplicate, and incubated for two hours and 15 min. in a Dubnoff shaker, at 
37°C, under an atmosphere of 95% 0 2 /5% C02 . At the end of the incubation 
the content of the tubes was added to siliconized glass tubes with round 
bottoms. Each teflon tube was rinsed with 0.5 ml distilled water, and this 
was added to the glass tubes. Then 5 ml dichloromethane (Merck) was added 
and the glass tubes were shaken by hand for 30 seconds, to extract the corti-
costerone to be measured. The aqueous layer containing cells and proteins 
was separated from the dichloromethane layer by centrifuging at 1200 X g for 
2 min. The upper, aqueous layer was removed using a water operated suction 
pump. Then, 4 ml dichloromethane containing the corticosterone, was pipetted 
into clean glass tubes with a flat bottom. A fluorescence reagent, consisting of 
30% absolute alcohol and 70% concentrated sulphuric acid, was then added to 
the glass tubes, each tube receiving 2 ml. The glass tubes were again shaken by 
hand for 30 sec. After 30 min. the upper layer consisting of dichloromethane was 
removed. 
The fluorescence was measured 60 min. after addition of the fluorescence 
reagent, using a spectrofluorimeter (Fluorimeter 1000 M, Perkin-Elmer) 
with an excitation wavelength of 473 nm, and an emission wavelength 
of 526 nm. This measurement of corticosterone is a modification of the 
method described by Silber et al. (4). For equilibration of the fluorescence 
curve we used samples of 0, 0.2, 0.6 and 1.0 11g corticosterone in 1 ml KRBG 
buffer plus 0.5 ml distilled water. The fluorescence readings of corticosterone 
were plotted against the standard ACTH series, using a logarithmic scale for the 
standard ACTH concentrations. 
The total number of adrenal cells obtained in each assay, and many variables 
in the incubation method, have been carefully evaluated by Mulder in his 
thesis (3). We were able to confirm the high correlation coefficient between 
the ACTH standard concentrations and the fluorescence readings found in this 
assay, ranging from 0.985 to 0.997 for the linear log dose response from ACTH 
standard 7 (6.15 pU/ml) to standard 3 (153.85 pU/ml). Theinterassayvariation 
in 4 bioassays of ACTH amounted to 6%. The intraassay variation was 10%. 
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!I.A.3. Radioimmunoassay of ACTH and corticosterone 
The plasma ACTH concentration and the ACTH content and release of 
the anterior lobe of the rat pituitary were occasionally also measured using a 
radioimmunoassay of plasma ACTH, as provided by the Radiochemical Centre 
Arnersham (Buckingham shire) {5). Preliminary extraction of plasma samples 
onto glass beads was carried out, as described by Ratcliffe and Edwards (6), 
while the pituitary media and contents were measured without extraction. The 
interassay variation was 7%. The intraassay variation amounted to 12%. Plasma 
corticosterone was measured with a competitive protein binding assay (7). 
ll.B. RESULTS 
The results obtained in order to study the value of the use of the transplantable 
ACTH/PRL secreting pituitary tumor 7315a, have been divided in the follow-
ing sections: 
1. The relation between the weight of the tumor and the weight oftheadrenals. 
2. The relationship between the weight of the tumor and the circulating con-
centrations of ACTH and corticosterone. 
3. The effect of the tumor on: 
a) anterior pituitary lobe weight. 
b) ACTH content of the anterior lobe 
c) ACTH release by the anterior lobe. 
4. The effect of adrenalectomy on ACTH content and pituitary weight. 
5. A comparison between the biological and radioimmunological activity of 
tumor ACTH. 
li.B.I. The relation between the weight of the tumor and the weight of the 
adrenals 
A linear relationship existed between the weight of the 7315a tumor and the 
total weight of the two corresponding adrenal glands (Fig.ll-1 ). The correlation 
coefficiem was F0.826 (p<O.OO 1). The data of three different experiments 
were pooled, the number of tumor-bearing rats being in total 59. The mean 
adrenal weight in the control non-tumor bearing animals of these three ex-
periments was 51.5 ± 2.1 mg (mean± S.E.M.; n=l8). 
l!.B.2. The relation between the weight of the tumor and the circulating con-
centrations of ACTH and corticosterone 
The plasma ACTH concentrations of 10 tumor-bearing animals amounted to 
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Fig. II-1. The correlation between tumor weight and adrenal weight in female rats carrying 
the ACTH/PRL secreting tumor 7315a. 
7668 ± 1190 pg/ml (mean± S.E.M.). There was a highly significant correlation 
between the weight of the tumor of these animals and the circulating ACTH 
levels (Fig. 11-2; r=0.823; p<O.OOI). In five control non-tumor-bearing rats 
plasma ACTH levels amounted to 241 ± 43 pg/ml. 
Plasma corticosterone levels of the 10 tumor-bearing rats mentioned above 
amounted to 46.2 ± 3.8 (.lg/100 ml, while the levels in 5 non-tumor-bearing 
controls were 19.6 ± 6.2 (.lg/100 ml (mean± SEM) (p<O.Ol vs. tumor-bearing 
control rats). There was no correlation between the total adrenal weight and 
circulating corticosterone levels, nor between the weight of the tumor and 
plasma corticosterone concentrations. The ACTH content of the anterior 
pituitary lobe was significantly depressed in tumor-bearing rats when compared 
with controls (see below), but this did not correlate with the circulating 
corticosterone levels. The plasma ACTH concentration did not show a cor-
relation with the amount of ACTH present in the anterior pituitary gland. 
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Fig. II-2. The correlation between plasma ACTH and tumor weight in female rats carrying 
the ACTH/PRL secreting tumor 7 315a. 
ll.B.3. The effect of tumor transplantation on the ACTH content and release 
of the anterior pituitary lobe 
A statistically significant reduction of the ACTH content of the anterior 
pituitary gland was consistently found in tumor-bearing rats. In Fig. ll-3 the 
effect of tumor transplantation on the ACTH content per total pituitary gland 
and per mg pituitary are shown as an example of the results obtained in three 
different experiments. (ACTH measured by bioassay and expressed in 1-!U/total 
gland or J1Ufmg pituitary). In Table 11-1 the results of ten different experiments 
ACTH 
(~U/glandl 
lO.OOO 
15.000 
10.000 
5.000 
' 
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Fig. JI-3. The effect of tumor transplantation on the ACTH content of the anterior 
pituitary gland expressed in ,u.U/total gland, and p,U/mg gland (hatched bars), in female 
rats in 3 different experiments (8 rats per group; mean± S.E.M; C =controls; T =tumor-
bearing rats). 
* p<0.02 
** p<O.OOS 
*** p<O.OOl 
are summarized, in which the significant reduction is also evident. The mean 
ACTH content per total pituitary is 10687 MU/gland, whereas the mean con-
tent in rats with a tumor is only 3395MU/gland (p<O.OOl), ranging from 6977 
to 16002 11U/gland and from 1821 to 5219 flU/total gland for controls and 
tumor rats respectively. When expressed per mg pituitary gland, the same 
reduction of ACTH content is observed, though In percentages a slightly 
smaller reduction is present. 
The release of ACTH from the anterior pituitary lobes Incubated in vitro 
for 4 hours of the same groups of rats, is presented in Table 11-11. The release 
of ACTH in vitro expressed per gland shows great variations, but a reduction in 
release is noted In tumor rats versus controls in all but two of the experiments 
(p<0.02). However, no significant reduction is present, when data are ex-
pressed in 11U ACTH per mg pituitary gland. The percentages of reduction of 
ACTH content In tumor rats versus controls ranged from 47.9%to 81.4%with 
a mean of 60.2% when measured per total gland. The percentage of change per 
mg pituitary ranged from 27.6% to 70.0% (mean 51.7%). There was no cor-
relation between these reductions in anterior pituitary ACTH content and 
tumor weight nor with absolute content and tumor weight (Table II-!11). 
The mean weight of the anterior lobes of the pituitary gland of control rats 
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Table II-I. The ACTH content per total anterior pituitary gland, and per mg anterior 
pituitary gland, in female control rats and tumor-bearing rats (6-8 per group) in 10 con-
secutive experiments 
ACTH content ACTH content 
(~U/total gland) (J,Ujmg gland) 
Controls Tumor Controls Tumor 
1 10023 ± 2016 5219 ± 654 938 ± 139 679 ± 81 
2 11617 ± 852 4087 ± 264 1044 ± 61 517 ± 20 
3 10124 ± 930 4401 ± 811 1190 ± 78 610 ± 112 
4 6977 ± 268 1981 ± 312 576 ± 34 309 ± 
5 10833 ± 637 2043 ± 346 936 ± 81 281 ± 
6 16002 ± 1572 3641 ± 503 1344 ± 138 477 ± 
7 10682 ± 399 2492 ± 274 860 ± 38 343 ± 
8 9767 ± 1250 3249 ± 505 760 ± 103 445 ± 
9 9808 ± 566 1821 ± 231 927 ± 77 306 ± 
10 11034 ± 883 5017 ± 566 1113 ± 68 715 ± 
x 10687 ± 710 3395 ± 403 969 ± 69 468 ± 
a a 
All values expressed as mean± S.E.M. inpU ACTH as measured by ACTH bioassay. 
X represents mean values of these 10 experiments. 
a p < 0.001 vs. controls. 
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was 11.56 ± 0.36 mg, while the mean pituitary weight of the tumor-animals 
was significantly reduced: 7.29 ± 0.18 mg (n = 25; p<O.OOI), a reduction in 
weight by 36.9%. There was no correlation between tumor weight and the 
reduced pituitary weight in 25 tumor-bearing rats. 
ll.B.4. The effect of adrenalectomy on the pituitary ACTH content and 
weight 
The effects of bilateral adrenalectomy (4 weeks before) were studied in control 
rats and in animals with a transplanted tumor (Table ll-IV).In adrenalectomized 
rats a marked rise in ACTH content was evident when compared with normal 
rats, the mean ACTH content per total gland rising from 18 800 ± 1400 pU in 
controls to 52 500 ± 12 700 pU in the adrenalectomized rats (p<0.02). 
As was to be expected, a significant fall in mean ACTH content of the 
anterior pituitary gland was found in tumor controls when compared with 
normal rats (4600 ± 1100 vs. 18 800 ± 1400; p<O.OOl). But, adrenalectomized 
rats with the transplanted ACTH/PRL secreting tumor demonstrated a likewise 
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Table II-II. ACTH release by anterior pituitary glands of control and tumor-bearing rats, 
incubated in vitro for 4 h 
ACTH release in medium ACTH release in medium 
(gU/total gland) (gU/mg gland) 
Controls Tumor Controls Tumor 
1 161.8 ± 37.7 86.4 ± 6.7 13.5 ± 3.0 10.5 ± 1.1 
2 41.3 ± 5.1 17.7 ± 3.4 3.3 ± 0.6 2.2 ± 0.4 
3 38.9 ± 2.7 27.6 ± 1.1 3.5 ± 0.3 3.6 ± 0.3 
4 30.5 ± 2.8 31.5 ± 5.5 2.5 ± 0.3 5.6 ± 1.6 
5 55.5 ± 8.0 24.9 ± 6.9 4.9 ± 0.9 3.3 ± 0.9 
6 86.7 ± 4.3 44.4 ± 13.7 8.4 ± 1.2 7.7± 1.9 
7 39.6 ± 4.9 11.1 ± 3.9 3.2 ± 0.4 1.6 ± 0.6 
8 16.9 ± 2.1 9.2 ± 2.5 1.3 ± 0.2 1.3 ± 0.3 
9 64.9 ± 6.4 69.7 ± 10.1 7.1±1.4 10.0 ± 1.4 
x 59.6 ± 14.5 35.8 ± 8.8 5.3 ± 1.3 5.1 ± 1.2 
a b 
All values expressed as mean± S.E.M. in J.l U ACTH as measured by ACTH bioassay. 
X represents mean values of these 9 experiments. 
a p < 0.02 vs.. control. 
b n.s. 
Table II-III The percentage of reduction (% change) of ACTH content in anterior lobe 
pituitary per gland and mg gland resp., in tumor-bearing rats versus controls, and the ab-
sence of a relationship with mean tumor weight (g) 
%Change of ACTH content Mean 
Gland mg Gland Tumor weight 
-64.8 -50.5 49.6 ± 10.8 
2 -56.5 -48.7 17.4 ± 4.6 
3 -71.6 -46.6 22.1 ± 2.2 
4 -81.3 -70.0 26.7 ± 3.5 
5 -77.3 -64.6 43.8 ± 11.0 
6 -76.7 -60.1 38.7 ± 7.1 
7 -66.8 -41.5 41.4 ± 13.3 
8 -81.4 -67.1 38.7 ± 8.3 
9 -54.5 -35.9 27.3 ± 5.2 
10 -47.9 -27.6 27.0 ± 6.3 
x -60.2 -51.7 33.3 ± 3.3 
a 
a 
a n.s. 
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increase in the ACTH content of the anterior pituitary lobes, which was highly 
significant in comparison with rats with a transplanted tumor and intact 
adrenals (39 500 ± 9 100 11U vs. 4 600 ± 1100 11U; p<O.OOl) (Table !I-IV). 
The same results were found, when ACTH content was expressed per mg 
pituitary. Moreover, there was no significant difference in ACTH content of 
the anterior pituitary gland of adrenalectomized rats versus adrenalectomized 
tumor-bearing rats (52 500 ± 12 700 11U vs. 39 500 ± 9100 11U resp.; n.s.). 
The weight of the tumor of the adrenalectomized animals did not differ from 
that in the control tumor-bearing rats. 
In Table ll-V data regarding the ACTH content per pituitary and the 
release of ACTH in vitro are summarized. The changes in the pituitary ACTH 
content in adrenalectomized rats and in tumor-bearing rats, who underwent 
also bilateral adrenalectomy, are essentially the same as described in Table 
II-IV. The changes are reflected in a similar way in the ACTH release from the 
anterior pituitary lobe in vitro: a significant rise of ACTH release occurred 
after bilateral adrenalectomy in both control and tumor-bearing groups (adrenal-
ectomy vs. controls: 156.6 ± 26.8 vs 41.5 ± 5.1 11U/total gland resp.; p<0.05; 
tumor+ adrenalectomy vs. tumor controls: 128.6 ± 16.0 vs. 17.7 ± 3.4 11U/ 
total gland resp.; p<O.Ol). Again, the release of ACTH in vitro amounted to 
comparable levels in both adrenalectomy and tumor + adrenalecomy groups 
(156.6 ± 26.8 vs. 128.6 ± 16.0 11U/total gland; n.s.) (Table !I-V). The per-
centages of changes in ACTH release by the anterior glands in vitro, and in 
pituitary ACTH content, plotted against the normal control group, amounted 
to -57% and -49% resp. in rats with a tumor only, to +278% and 331% resp. in 
Table Jl.Jv. The effects of bilateral adrenalectomy on the ACTH content of the anterior 
pituitary of control and tumor-bearing rats, expressed per total gland and per mg pituitary 
Controls 
(n = 5) 
Tumor controls 
(n = 5) 
Adrenalectomy 
(n = 5) 
Tumor+ adrenalectomy 
(n = 5) 
ACTH content 
(~U/gland) 
!8000± 1400 
4 600 ± I !OO" 
52 500 ± 12 700c 
39 500 ± 9 100b,c 
ACTH in ,uU/gland and ,uU/mg pituitary; 5 rats per group; mean± S.E.M. 
a p < 0.001 vs.. controls. 
b p < 0.001 vs. tumor controls. 
c p < 0.02 vs. controls. 
ACTH content 
U,U/mg gland) 
1644 ± 181 
592 ± 121" 
4277 ± lllc 
4074 ± 7!3b,c 
Table II~ V. Effects of bilateral adrenalectomy on ACTH release by the anterior pituit~ry gland in vitro (in JLU/gland, and ~tU/mg gland) and its ACTH 
content (in ~tU/gland, and ~tU/mg gland) of control rats and rats with a transplanted tumor (5 per group± S.E.M.) 
Controls 
(n = 5) 
Tumor controls 
(n = 5) 
Adrenalectomy 
(n = 5) 
Tumor+ a-drenalectomy 
(n = 5) 
a p < 0.05 vs. controls. 
b p < 0.01 vs. tumor controls. 
ACTH release in vitro 
{!tU/total gland) 
41.5± 5.1 
17.7 ± 3.4" 
156.6 ± 26.8a 
128.6 ± 16.oa,b 
(!tU/mg gland) 
3.3 ± 0.6 
2.2 ± 0.4 
12.9 ± 2.2a 
15.1 ± 3.4a,b 
ACTH content 
(!tU/total gland) 
17040± 2770 
8680 ± 310a 
73600 ± 16880a 
81800 ± 11780a,b 
(!tU/mg gland) 
1340 ± 24 
105 ± 6a 
600 ± 137" 
931 ± 203a,b 
w 
__, 
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adrenalectomized control rats, and to +211% and 381% resp. in rats with a 
tumor and adrenalectomy. 
The effects of adrenalectomy of control animals and tumor-bearing rats on 
the anterior pituitary weight showed no difference in adrenalectomized control 
rats vs. intact controls (12.6 ± 0.8 vs. 11.7 ± 0.8 mg; n=S; n.s.) and a significant 
increase in adrenalectomized tumor-bearing rats vs. tumor controls (9.36 ±0.75 
VS. 7.48 ± 039 mg; p< 0.05) (Fig. IJ-4). 
ll.B.S. A comparison between the biological and radioimmunological activity 
of tumor ACTH 
The 7315a tumor turned out to secrete an ACTH-Iike polypeptide with a 
relatively low biological activity. The bio-activity of the plasma samples ofthe 
10 tumor-bearing rats mentioned under ll.B.2. amounted to only 5% of the 
concentration measured with the specific radioimmunoassay. 
When the total content of ACTH in the anterior lobe of the pituitary was 
determined by RIA and bioassay, however a linear relationship was found, with 
a high correlation coefficient (r=0.95). So there is a highly significant cor-
relation between both methods (p<O.OOJ) (Fig. 11-5). When the release of 
ACTH from the pituitary was measured, after incubation of the anterior lobes 
during four hours, again a significant correlation was observed (r=0.94; 
p<O.OOl). 
lLC DISCUSSION 
The finding of a linear relationship between the plasma ACTH concentration 
and the weight of the pituitary tumor and between the weight of the tumor 
and the adrenal weight demonstrated the profound influence of this tumor 
on the adrenal gland: it caused a tumor weight dependent hyperplasia of 
the adrenals. Whereas the normal adrenal weight of these rats amounts to 
around 50 mg, tumors of 30-40 grams may produce a four- to five-fold in-
crease in adrenal weight. It is evident that this increase is mainly caused by the 
large amounts of ACTH secreted by this tumor, a situation comparable with 
the existence of Cushing's syndrome in man, caused by an ectopic ACTH 
production. 
The comparison of the plasma ACTH levels obtained by radioimmunoassay 
and bioassay respectively, suggests that this tumor produces mainly inactive 
parts or incomplete aminoacid residues of the ACTH polypeptide and that only 
5% of the circulating "ACTH-molecules" is biologically active. Still, this amount 
seems to be high enough to induce the marked changes in adrenal weight and 
the doubling of circulating plasma corticosterone levels. 
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Fig. 11~4. The mean anterior pituitary weight (in mg ± S.E.M.) in control rats (C); adrena-
lectomized rats (A); tumor controls (TC); and adrenalectomized tumor rats (T A) (6 
female rats per group). 
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Fig. II-5. The correlation of ACTH content per anterior pituitary gland as measured by 
radioimmunoassay (in ng/gland) and by bioassay (in ,uU/gland). 
One may speculate on the contribution of hyperprolactinemia to the 
enormous increment in the size of the adrenal gland. Recent experiments with 
a pure PRL-secreting tumor derived from the 7315a tumor, however, showed 
a normal weight of the adrenal gland in the presence of plasma PRL levels 
above 10 000 ng/ml (unpublished data). The absolute corticosterone levels 
of the plasma in 7315a tumor-bearing rats were only doubled in comparison 
with those of control rats. However in man the actual levels of plasma gluco· 
corticoids have been reported to show a poor correlation with the cortisol 
secretion rate measured over 24 hrs in patients with severe Cushing's syndrome. 
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These more extensive peripheral effects of marginally elevated plasma cortisol 
levels may be ascribed to the disappearance of the circadian rhythm of ACTH 
and cortisol secretion resulting in persistingly (slightly) elevated plasma cortisol 
levels over 24 hrs. 
The marked reduction of the anterior pituitary weight in rats with a trans-
planted tumor is not entirely due to the conspicuous changes in the pituitary-
adrenal system. An important contribution is made by the excessive pro-
duction and secretion of prolactin by the transplanted tumor, which has a 
concomitant suppressive effect on prolactin producing pituitary cells, resulting 
in an additional reduction in pituitary weight. The quantitative importance of 
prolactin may be stressed by the fact that the prolactin content of the pituitary 
is about 250 !lg in control rats and 80-100 11g/total pituitary in tumor-bearing 
rats, while the ACTH content when measured with radioimmunoassay has to 
be expressed in ng/pituitary, a difference of a factor 1000 (8). 
A constant reduction in the pituitary ACTH content was found in all rats 
with the transplanted ACTH/PRL secreting tumor, indicating an impaired 
synthesis. A similar reduction in the release of ACTH per total anterior pituitary 
in vitro is noted, which might well be considered as an impaired secretory 
potency. One may speculate on the mechanism of this persistent reduction. 
There is some evidence, though scattered, that high levels of ACTH, admin-
istered into the median eminence of the hypothalamus, might influence the 
secretion of ACTH from the pituitary through a "short" loop feedback system 
on its own secretion {9, 13) (see section I.B.3.). Jones et al. found that in-
creasing concentrations of ACTH were able to inhibit CRF release by hypo-
thalami incubated in vitro (! 0). On the other hand there is abundant evidence 
of a strong negative feedback system, in which glucocorticoids exert an in-
hibition of CRF and ACTH synthesis and release (see section I.B.2.). 
In our opinion this mechanism is mainly involved in the suppression of 
pituitary ACTH synthesis, and in the inhibition of pituitary ACTH secretion 
in the 7315a tumor-bearing rats. The synthesis of biologically active ACTH 
by the ACTH/PRL tumor, and subsequent secretion into the systemic cir-
culation, produces bilateral adrenal hyperplasia. Adrenal corticosterone pro-
duction is stimulated and the secretion from these hyperplastic adrenals is en-
hanced. The high circulating corticosterone concentrations exert, via a ne-
gative feedback mechanism, a suppressive influence on CRF release, and ACTH 
synthesis and release. Important evidence for the existence of this sequence of 
events is presented by the data obtained in the adrenalectomy experiments. 
Bilateral adrenalectomy of control rats without a tumor produced an enormous 
rise in the ACTH content, and release from the anterior pituitary, as was shown 
in many previous similar experiments (10, ll ). In adrenalectomized rats 
carrying the ACTH/PRL secreting tumor a similar significant rise in pituitary 
ACTH content was found when compared with rats with the same trans-
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planted tumor, and without bilateral adrenalectomy. It was demonstrated 
that the release of ACTH from the anterior pituitary was also significantly 
stimulated. Moreover, no significant differences were found in these experi~ 
ments between adrenalectomized control rats and adrenalectomized tumor~ 
bearing rats. 
These data can be explained in only one way: apparently bilateral adrena-
lectomy is able to abolish completely the suppression of the ACTH synthesis 
and release by the anterior pituitary gland found in tumor-bearing rats. This 
implies that the continuous elevation of circulating corticosterone concen~ 
!rations is the most important factor causing this pituitary suppression. The 
negative feedback mechanism by plasma corticosterone regulates the activity 
of the hypothalamo·pituitary-adrenal axis. In consequence, it is concluded 
that the large amounts of ACTH released into the systemic circulation from 
this ACTH/PRL secreting tumor do not exert a direct effect on the synthesis 
and release of ACTH by the pituitary. This implies that the importance of a 
"short" loop feedback mechanism of ACTH on its own secretion {by in-
hibiting CRF release") is in this model not a very dominant one. One should 
bear in mind that most experiments, that have described this phenomenon in 
the literature were done either in vitro or with the use of hypothalamic implants, 
which does not necessarily implicate physiologic conditions (see section l.B.3.). 
lt may be clear from the considerations mentioned above, that the model 
of the ACTH/PRL secreting tumor offers many advantages in studying the 
suppression of the hypothalamo-pituitary system in vivo. As mentioned earlier, 
this tumor mimicks hypercortisolism in man caused by an ectopic ACTH 
producing tumor. Furthermore, this model might be applied to the investigation 
of mechanisms involved in the suppression of the HPA-axis, induced by exo-
genous glucocorticoids and the recovery of part of this axis after withdrawal of 
steroids. The common denomjnator is in both circumstances the presence of con-
tinuously high circulating glucocorticoid concentrations, which are responsible 
for the development of Cushing's syndrome. A diagram may further exemplify 
this (Table ll-Vl). We wanted to use the model of this transplantable tumor, 
instead of long-term administration to rats of high doses of glucocorticoids 
parenterally or via the drinking water, in order to be sure of persistently 
high levels of circulating corticosterone with low variability during three or 
four weeks in large groups of rats. This aim turned out to be difficult to 
achieve when using exogenous glucocorticoids in studies with rats (12). 
ll.D. CONCLUSIONS 
l) The subcutaneous implantation of the ACTH/PRL secreting tumor 7315a 
in rats causes a suppression of the synthesis and release of ACTH in the 
anterior pituitary lobe. 
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Table II- VI Sequence of events in the presence of ectopic ACTH production by the ACTH 
secreting tumor in rats, and of administration of high doses of glucocorticoids in man 
RAT 
Ectopic production of ACTH by the 
ACTH secreting tumor 
+ 
Bilateral adrenat hyperplasia 
High circulating corticosterone 
concentrations 
Suppression of synthesis and secretion 
of ACTH in/from the anterior pituitary 
MAN 
Exogenous administration of 
glucocorticoids 
+ 
High circulating glucocorticoid levels 
in the systemic circulation 
+ 
Suppression of synthesis and secretion 
of ACTH in/from the anterior pituitary 
+ 
Suppression of production and secretion 
of cortisol from the adrenals 
+ 
Bilateral atrophy of the adrenals 
2) This suppression is mediated by a negative feedback mechanism, in which 
the high circulating corticosterone concentrations from hyperplastic adrenal 
glands are the main determining factor. 
3) The high circulating levels of plasma ACTH, secreted by the transplanted 
tumor, probably do not directly exert a significant suppression on the 
synthesis of ACTH by the anterior pituitary. A "short" ioop negative feed-
back mechanism seems not to play an important role in this tumor model. 
4) This tumor model is therefore comparable with the situation, in which 
high concentrations of circulating glucocorticoids cause suppression of 
CRF and ACTH release. 
REFERENCES 
1. MacLeod R.M., Abad A., Eidson L.L In 11ivo effects of sexhormones on the in vitro 
synthesis of prolactin and growth hormone in normal and pituitary tumor-bearing 
rats. Endocrinology 1969; 84: 1475-1483. 
2. Lamberts S.W.J., MacLeod R.M. The inability of bromocriptine to inhibit prolactin 
secretion of transplantable rat pituitary tumor: observations on the mechanism and 
dynamics of the autofeedback regulation of prolactin secretion. Endocrinology 
1977; 104: 65-70. 
3. Mulder G.H. Release of ACTH by rat pituitary ceHs. Thesis Amsterdam, 1975. 
4. Silber R.H., Busch R.D., Os Lapas R. Practical procedure for estimation of corti-
costerone or hydrocortisone. Clin. Chemistry 1958; 4: 278-285. 
44 
5. Radiochemical centre, Amersham, Buckinghamshire, England. ACTH immuno-
assay kit; code JM 66. Description and details of procedure. 
6. Ratcliffe J.G., Edwards C.R.W. The extraction of adrenocorticotrophin and arginine-
vasopressin from human plasma by porous glass. In: Kirkham K.E., Hunter W.M., 
ed. Radioimmunoassay methods. Edinburgh; Churchill Iivingstone, 1971: 501-512. 
7. Jong de F.H., Molen van der H.J. Determination of dehydroepiandrosterone and 
dehydroepiandrosterone sulphate in human plasma using electron capture detection 
of 4-androstene-3,6,17-trione after gas-liquid chromatography. J. Endocr. 1972; 
53: 461-474. 
8. Lamberts S.W.J., Nagy I., Uitterlinden P., MacLeod R.M. The effect of catechol-
estrogens on the growth of prolactin-secreting pituitary tumors and normal pro-
lactin synthesis in the rat. Endocrinology 1982; 110: 1141-1146. 
9. Motta M., Mangili G., Martini L. A '"short" feedback loop in the control of ACTH 
secretion. Endocrinology 1965; 77: 392-395. 
10. Bristow A.F., Gleed G., FauchCre J.L., Schwijzer R., Schulster D. Effects of ACTH 
analogues on steroidogenesis and cyclic AMP in rat adrenocortical cells. Biochem J. 
!980; !86: 599-603. 
11. Jones M. T., Hillhouse E., Burden J. Secretion of corticotrophin-releasing hormone 
in vitro. Frontiers in neuroendocrinology 1976;4: 195-226. 
12. Lamberts S. W.J. Cortisol en vetweefsel. Thesis, Rotterdam, 1975. 
Chapter III 
Effects of putative neurotransmitter enhancing 
drugs on the hypothalamo-pituitary axis of 
tumor bearing rats 
liLA. INTRODUCTION 
In the previous chapter we have described the effects of the transplantable 
ACTH/PRL producing tumor 7315a on pituitary ACTH synthesis and re-
lease. We also discussed the feasability of this experimental model to study the 
effects of high circulating glucocorticoid levels on pituitary ACTH synthesis 
and release. As stressed previously, the conditions of the hypothalamo-pituitary 
axis in this model are comparable with those of man during exogenous glu-
cocorticoid administration. 
As chronic suppression of the ACTH content of the anterior pituitary of 
tumor-bearing rats in the presence of high circulating corticosterone levels was 
a constant feature, we were interested to know whether prevention or abolish-
ment of this suppression was possible. If ACTH synthesis could be stimulated 
by enhancing CRF release, even in the simultaneous presence of high cir-
culating corticosterone concentrations, potentially a way might be opened to 
prevent suppression of the hypothalamo-pituitary axis in man during the 
administration of pharmacologic doses of glucocorticoids. 
We have tried to influence pituitary ACTH synthesis and release in tumor-
bearing rats with pharmacologic agents which are assumed to exert a stimulatory 
effect on CRF release, through modulation of excitatory neurons. We have 
thus concentrated mainly on the serotonergic and cholinergic pathways. 
Furthermore, we looked for pharmacologic agents able to penetrate the blood-
brain barrier. Finally, all drugs had either to be available as drugs registered and 
approved by the Netherlands drug administration or to be known as having a 
low toxicity without important side-effects. Applying these criteria, a drug 
found to be able to prevent the suppression of pituitary ACTH synthesis and 
release in the tumor-bearing rat, might subsequently be shown to be able to do 
the same in man. 
It has been mentioned in chapter I that the effects of many serotonergic and 
cholinergic drugs on the activity of the HPA-axis have already been studied in 
detail. However, most of these experiments evaluated the effects of the various 
substances on the HP A-axis under basal or stress conditions. Reports on the 
actions of these drugs in the simultaneous presence of high circulating gluco-
corticoid concentrations are very few (1). 
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In this chapter we describe the effects of the following pharmacologic 
agents on the pituitary ACTH content and release in tumor-bearing rats. The 
drugs can be categorized according to their presumed specific pathway: 
A. serotonin - enhancing: 
1- chlorimipramine 
2- fenfluramine 
B. acetylcholine- enhancing: 
1- piperidine 
2- carbachol {2-carbamo yl}oxy-ethyl-t rimethylammoniumchloride) 
3- CDP-choline (cytidine-diphosphatocholine) 
4- pyridostigmine 
The potential serotonin enhancing effects of antidepressants have been de-
monstrated by Sigg et al. {2) and Lahti and Barsuhn (3). Chlorimipramine 
appears to be a strong serotonin re-uptake blocker, which results in rising ACTH-
levels and thus causes a rise in circulating corticosterone levels in rats. The 
enhancement of serotonergic neurotransmission by fenfluramine was recently 
reviewed by Fuller {4, 5). Fenfluramine, as a serotonin releasing drug was able 
to stimulate plasma corticosterone concentrations in rat. Carbachol, CDP-
choiine and pyridostigmine are nicotinergic cholinergic agents, while piperidine 
is a specific nicotinic cholinergic receptor agonist (6). 
lll.B. METHODS 
To evaluate the effects of the various pharmacologic agents we used Buffalo 
rats, weighing 200-220 g, inoculated with the transplanted ACTH/PRL se-
creting pituitary tumor 7315a. The agents to be injected were administered, 
when the size of the transplanted tumor was about 1.5 X 1.5- 2 X 2 em 2 . We 
used either subcutaneous or intraperitoneal injections. 
Chlorirnipramine (AnafraniiR, Geigy) was obtained in ampoules with 12.5 
mg/ml. The drug concentration was diluted with saline 0.9%, to get suitable in-
jection volumes of 0.25 ml, 0.3 ml, or 0.5 ml. In total, rats received chlor-
imipramine in doses of 0.5, 1.0, 1.5, 2.0 and 3.0 mg/day/rat (2, 3). The drug 
was injected twice daily for five days, or once a day for 12 days, s.c. 
Fenflurarnine (PonderaJR, fenflurarninechloride, Servier) tablets of 20 mg 
were dissolved in saline 0.9%, and 0.25 ml or 0.5 ml of this solution was in-
jected intraperitoneally once a day to total doses of resp. 0.8, 1.6, 2.0, 3.2 mg/ 
day/rat. The period of injections was 5, or 12 days. 
Piperidine chloride crystals (Merck) were dissolved in saline 0.9% and doses of 
resp. 0.375 and 0.5 mg/day/rat were injected i.p. once a day, for 5, 13 or 14 
days. 
Carbachol (DorylR, Merck) in ampoules of 0.25 mg/ml was diluted with 
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saline 0.9%, and rats were given doses of resp. 0.062 and 0.10 mg/day/rat for 5 
days, divided over two doses s.c. 
Pyridostigmine (MestinonR, Roche) in ampoules of 5 mg/ml was diluted 
with saline 0.9%, rats received 60 Jlg/day for 5 days i.p. 
Cytidine-diphosphatocholine (CDP-cholineR, Sigma) was dissolved in saline 
and rats received 1 mg/day/rat for 5 days, once daily i.p. In all experiments 
injection volumes ranged between 0.2- 0.5 mL 
The number of rats varied per experiment from 5-8 per group, which will 
be specified for each experiment separately_ All tumor-bearing controls re-
ceived saline 0.9% injections i.p. The last injection was given one hour before sa-
crificing the rats. Rats were decapitated without preceding ether anesthesia. 
The anterior lobe of the pituitary was removed, and incubated for 4 hours, 
when studies of the release of ACTH in the medium were planned. The tumor, 
and sometimes the adrenals were removed, cleaned of surrounding adipose 
tissue and weighed. The ACTH content of the anterior pituitary and its release 
into the medium was measured with the ACTH bioassay. For further, detailed 
information on the procedures we may refer to the previous chapter (li.A.2.). 
!II.C. RESULTS 
l!LC.l. Ch/orimipramine 
After 5 days of injection s.c. of chlorimipramine (resp. 0.5, 1.5, 3.0 mg/day/rat 
divided over two doses) in tumor-bearing rats, the ACTH content of the 
anterior pituitary increased significantly compared with tumor-bearing con-
trols, when expressed per total gland, as well as per mg pituitary (tumor + 
chlorimipramine 1.5 mg and 3.0 mg vs. tumor controls p<O.Ol and p<0.005, 
resp. (Fig. 1!1-1)). No significant increase was noted when the rats received 
chlorimipramine 0.5 mg/day. The suppression of pituitary ACTH content as 
seen in tumor-bearing controls, was completely overcome, and the levels of 
the ACTH content in the groups with the higher chlorimipramine doses were 
fairly equal to the ACTH content of control rats without an ACTH secreting 
tumor. The mean anterior pituitary weight in tumor-bearing rats injected with 
chlorimipramine was not different from that in tumor controls (resp. 7.77 ± 
0.13 mg; 7.60 ±0.28 mg; 7.86 ±0.40vs.7.66 ±0.17mg;n.s.). Likewise there 
were no significant differences between the tumor weight in the various groups 
with a tumor (21.0 ± 6.9 g; 12.6 ± ll.4g; 17.9 ±6.1 vs.27.0 ±6.3 g) and also 
not of the weight of the adrenal glands. In another experiment, tumor-bearing 
rats received chlorimipramine 2.0 mg/day/rat, for 5 days divided over two 
doses: the pituitary ACTH content in the chlorimipramine treated group rose 
to 11646 ± 147 4 flU/total gland (mean ± S.E.M.) compared with 5778 ± 
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Fig. III-1. The effect of chlorimipramine on the ACTH content of the pituitary gland in 
,uU/gland and ,uU/mg gland (hatched bars), in female rats. (5 rats per group; mean ± 
S.E.M.; C = controls; T = tumor-bearing rats; CHL-IMI = chlorimipramine 0.5 mg/day, 
1.5 mg/day; 3.0 mg/day; 5 days; twice daily). 
* p<0.005 
** p<O.Ol 
1478 /.lU/total gland in the tumor controls (p<0.002; n~5). The pituitary 
ACTH content of non-tumorbearing control rats was 18694 ± 1347 l.lUftotal 
gland and thus considerable higher than in the experiment mentioned before. 
Other similar experiments with chlorimipramine in the same doses confirmed 
this rise in pituitary ACTH content. 
We measured ACTH release into the medium from the anterior pituitary 
gland of chlorimipramine treated tumor-bearing rats. During incubation of the 
pituitary for 4 hours, the ACTH release into the medium from a group of 8 
rats, who received chlorirnipramine 2 mg/day /rat (twice daily) for 12 days, was 
significantly higher, when compared with control rats with and without a 
tumor (Table lll-1; p<0.05 and p<0.05 resp.). The same results were found 
when data were expressed per mg pituitary, and thus taking into account the 
diminished pituitary weight in tumor-bearing animals (Table !Il-l). 
In two of three other experiments, in which the pituitaries were incu-
bated for 4 hours, the chlorirnipramine treated groups (2 mg/day for 12 days 
once daily, or 3 mg/day for 5 days, twice daily) also showed a rise in the 
release of ACTH into the medium in comparison with the tumor control 
Table III-I. The effect of chlorimipramine on the ACTH content and the release of ACTH in medium per total pituitary gland, and per mg pituitary gland 
in female rats 
Controls 
(n= 7) 
Tumor controls 
(n = 6) 
Tumor + chlorimipramine 
(n = 8) 
ACTH (MU/lotal gland) 
Content 
11034 ± 853 
5018 ± 567 
7348±7llb 
ACTH (MU/mg gland) 
Medium Content 
64.9 ± 6.4 1!!3 ± 68 
69.7 ± 10.1 715 ± 53 
92.0 ± 13 .8a,b 1074 ± 108b 
ACTH in ,uU/gland and ,uU/mg gland; 6-8 rats per group; mean± S.E.M. Chlorimipramine: 2 mg/day, 12 days, twice daily. 
a p < 0.05 vs. controls. 
b p < 0.05 vs. tumor controls. 
c n. s. vs. tumor controls. 
Medium 
7.1±1.4 
10.0 ± 1.4 
13.4 ± 2.0a,c 
it 
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groups (Table lll-ll). Again, there was a similar increase in pituitary ACTH 
content in chlorimipramine treated rats, and no significant difference in mean 
pituitary, tumor or adrenal weight. Adrenal weight for example in one ex-
periment: tumor controls vs. chlorimipramine: 191.5 ± 3.6 vs. 212.3 ± 26.8 mg 
resp.; n.s. 
lll.C.2. Fenjluramine 
The effects were investigated of administration of two doses of fenfluramine 
(0.8 and 1.6 mg/day/rat for 5 days) on pituitary ACTH content in the tumor-
bearing rats. Fenfluramine 0.8 mg/day, twice daily caused a significant in-
crease in ACTH content (4455 ± 783 110/total gland vs. 2469 ± 208 110/total 
gland in tumor controls; p<0.05). The higher dose of fenfluramine 1.6 mg/day, 
twice daily did not significantly increase the ACTH content of the pituitary, 
(3692 ± 719 vs. 2469 ± 208 110/total gland; n.s.) (Fig. lll-2). In another 
experiment using a higher dose offenfluramine (3.2 mg/day for 5 days) pituitary 
ACTH content was 3332 ± 451 vs. 1981 ± 312 110/total gland in tumor-
control rats (p<0.02). 
In yet another experiment, in which tumor··bearing rats were given fenflu· 
ramine 2 mg/day/rat (one injection, for 12 days) there was again a rise in 
pituitary ACTH content and also in the release of ACTH after incubation 
during 4 hours (Table lll-lll; p<0.05), when compared with tumor controls. 
However, the effects of fenfluramine in causing an increase in ACTH release 
into the medium, were less consistent than the effects of chlorimipramine. ln 
two other experiments using doses of fenfluramine of less than 3 mg/day there 
was no detectable difference in the ACTH release in the drug treated and 
tumor control group. 
Table III-II. The effect of different doses of chlorimipramine, with different duration of 
administration, on the release of ACTH in medium per total pituitary gland, in female rats 
Controls 
Tumor controls 
Tumor + chlorimipramine 
ACTH (!;U/total gland) 
55.5 ± 8.0 
24.9 ± 6.9 
44.4 ± 1!.6a 
2 mg/12 days 
16.9±2.1 
9.2 ± 2.5 
13.1 ± 1.63 
2 mg/12 days 
30.5 ± 2.8 
31.5 ± 5.5 
35.1 ± 7.7b 
3 mg/5 days 
ACTH in gl.J/gland; 5~6 rats per group; mean± S.E.M. Chlorimipramine 2 mg/day, 12 days, 
once daily; chlorimipramine 3 mg/day, 5 days, twice daily. 
a p < 0.05 vs. tumor controls. 
b n.s. vs. tumor controls. 
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Fig. III-2. The effect of fenfluramine on the ACTH content of the pituitary gland in 
~-~.U/gland and J.LU/mg gland (hatched bars), in female rats. (5 rats per group; mean ± 
S.E.M.; C = controls; T = tumor~bearing rats; FENFLUR = fenfluramine 0.8 mg/day; 
1.6 mg/day; 5 days; twice daily). 
* p<O.OS 
III.C.3. Piperidine 
Piperidinechloride, used in two different concentrations (0.375 and 0.5 mg/ 
day/rat; two injections i.p. for 5 days), caused in three experiments a marked 
rise in the ACTH content of the anterior pituitary glands; piperidine 0.375 mg: 
7528 ± 1212 vs. 4401 ± 811 !!U/total gland in tumor controls;p=0.05;piper-
idine 0.5 mg: 3742 ± 435 vs. 2326 ± 181 11U/total gland in tumor controls; 
p<0.025. In the third experiment (Table lll-IV) the pituitary content and 
release of ACTH were simultaneously studied: both the release and the content 
increased after piperidine administration (0.5 mg/day, 5 days, twice daily) 
significantly (p<O.OS), when compared with tumor-bearing control animals. 
lll.C.4. Other cholinergic drugs 
The effect of the other cholinergic drugs on the pituitary ACTH content, as 
used in this tumor model were less clear. In Table lll-V the effects of two 
u, 
N 
Table JJJ.IJI. The effect of fenfluramine on the ACTH content and the release of ACTH into the medium per total pituitary gland, and per rug pituitary 
gland 
Controls 
(n ~ 7) 
Tumor controls 
(n ~ 6) 
Tumor + fent1uramine 
(n ~ 8) 
ACTH (.uU/total gland) 
Content 
11034 ± 833 
5018 ± 567a 
7140 ± 679b 
ACTH (~Ufmg gland) 
Medium Content 
64.9 ± 6.4 1113±68 
69.7 ± 10.1 715 ± 53a 
102.2 ± 16.4a,b 922 ± 72b 
ACTH in J.LU/gland and J.LU/mg gland; 6-8 rats per group; mean± S.E.M. Fenfluramine 2 mg/day, 12 days, once daily. 
a p < 0.05 vs. controls. 
b p < 0.05 vs. tumor controls. 
Medium 
7.1 ± 1.4 
10.0 ± !.4 
15.1 ± 2.9a,b 
Table III-IV. The effect of piperidine on the ACTH content and the release of ACfH into the medium per total pituitary gland and per mg pituitary 
gland in female rats 
ACTH (pU/total gland) 
Content Medium 
Controls 6977 ± 267 30.5 ± 2.8 
(n" 5) 
Tumor controls 1981 ± 311 3L5 ± 5.5 
(n "6) 
3093 ± 434b 58.3 ± !8.la,b Tumor+ piperidine 
(n" 6) 
ACTH in ,uU/gland and ,uU/mg gland; 5-6 rats per group; mean± S.E.M. Piperidine 0.5 mg/day, 5 days, twice daily. 
a p < 0.05 vs.. controls. 
b p < 0.05 vs. tumor controls. 
ACTH (pU/mg gland) 
Content 
573 ± 34 
298 ± 39 
438 ± sob 
Medium 
2.5 ± 0.3 
5.6 ± L5 
9.1 ± 3.3a,b 
U> 
w 
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Table Ill- V. The effect of carbachol on the ACfH content per total pituitary gland and per mg pituitary gland in female rats 
Controls 
(n = 6) 
Tumor controls 
(n = 5) 
Tumor+ carbachol 
(n = 5) 
ACTH content 
Total gland mg Gland 
22990 ± 2240 2206 ± 110 
10020 ± 1580 1218 ± 191 
10830 ± 1800" 1550 ± 214" 
0.062 mg/5 days 
ACTH content 
Total gland mg Gland 
23210 ± 3510 2179 ± 250 
4460 ± 610 569 ± 36 
3610 ± 340" 495 ± 45" 
0.1 mg/5 days 
ACTH in ,uU/gland and J.tU/mg gland; 5-6 rats per group; mean± S.E.M. Carbachol 0.062 mg/day, 5 days, twice daily; carbachol 0.1 mg/day, 5 days, 
twice daily. 
a n.s. vs. tumor controls. 
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doses of carbachol on the total pituitary content of tumor-bearing animals are 
summarized: it is clear that carbachol has no obvious effect in augmenting the 
ACTH content. 
Efforts to induce an increase in the pituitary ACTH content with CDP-
choline or pyridostigmine remained fruitless. In experiments with CDP-choline 
(I mg for 5 days) and pyridostigmine (0.06 mg/day i.p. for 5 days) the total 
ACTH content of the pituitary was not significantly different from the pituitary 
content in tumor·bearing control rats. 
!II.D. DISCUSSION 
It is clear from the results obtained in this chapter, that some of the pharma-
cologic agents used, are able to prevent the suppression of the pituitary ACTH 
release and content of rats bearing the ACTH/PRL secreting tumor 7315a. We 
have demonstrated in chapter II that the secretion of ACTH from the trans-
planted tumor has no profound depressing influence on the pituitary ACTH 
content, which stresses the importance of the high circulating corticosterone 
concentrations in inducing this suppression. Thus, the glucocorticoid induced 
suppression of CRF release from the hypothalamus and the subsequent in-
hibition of pituitary ACTH synthesis and release can be overcome by the 
administration of pharmacologic agents, known from the literature to stimulate 
CRF release. 
Chlorimiprarnine (Anafrani!R, Geigy) is a tricyclic antidepressant, fre-
quently used in the psychiatric field in dosages ranging from I 00 to 150 mg 
per day (15). Chlorimiprarnine induced consistently an increase in the ACTH 
content of the anterior pituitary gland, to levels comparable with the pituitary 
ACTH content of control rats without a tumor. Thus, chlorimipramine is able 
to prevent or reverse completely the suppression of the ACTH synthesis and 
release, even in the presence of the high circulating corticosterone concenw 
!rations characteristic for this experimental model. We found no significant 
differences in tumor weight or in the weight of the hyperplastic adrenals in 
tumor-bearing animals, whether or not treated with chlorimipramine. Thus it 
might be concluded that this compound influenced pituitary ACTH synthesis 
and release at the hypothalamic or pituitary level, and not at the adrenal level. 
Moreover, a dose-reponse relationship appears to be present, considering the 
progressive increase in ACTH content with higher doses of chlorimiprarnine 
(Fig. III-I). In the highest dose used (3.0 mg/day) the pituitary ACTH content 
had normalized (compared with controls) and no further increase was noted. 
The release of ACTH from the anterior pituitary was also stimulated by chlor-
imiprarnine given for 5 or 12 days. In each experiment ACTH release increased 
to levels similar to that found in normal controls, or rose even above levels 
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found in the medium of the pituitary glands from normal control animals. 
Again, as mentioned in chapter ll, the release of ACTH into the incubation 
medium from the pituitary of tumor-bearing controls was not always less than 
that of nonnal controls. After all, only 1-2% of the total pituitary ACTH con-
tent is released during the 4 hr incubation period into the medium. As both the 
total pituitary ACTH content, and the release of ACTH increased after chlor-
imipramine administration, this indicates probably a stimulation of ACTH 
synthesis and secretion. 
As mentioned before, Sigg et al. and Lahti and Barsuhn (2, 3) reported on 
the potentiating effect of tricyclic antidepressants on serotonin. They found 
that chlorimipramine (1 0 mg/kg i.p .) is a strong serotonin re-uptake blocker 
which enhances the effect of pretreatment with 5-hydroxytryptophan on 
plasma glucocorticoids. They concluded that chlorimipramine stimulated 
ACTH secretion through serotonergic pathways. Fuller explained the me-
chanism of the stimulating actions of serotonin re-uptake blockers (4, 5). 
After re-uptake inhibition, the serotonergic neuron decreases the synthesis 
and turnover of serotonin. The concentration of already released serotonin 
in the synaptic cleft is increased, and enhances the stimulative serotonergic 
action on the CRF neuron, due to blockage of re-uptake of serotonin (7, 8). 
Re-uptake is assumed to be the major means by which serotonin is inactivated 
at the neural synapse, so this type of compounds should facilitate neurotrans-
mission by serotonergic pathways (8, 22). 
Further evidence that serotonin re-uptake inhibition induces an increase in 
serotonergic functions, includes a) the ability of other selective inhibitors of 
serotonin like fluoxetine, zirnelidine, paroxetine, p-bromo-EXP 56, and Org 
6582 to raise corticosterone concentrations in plasma ( 4 ); and b )the in effectivity 
of a structural isomer of fluoxetine to enhance steroidogenesis when certain 
terminal groups are not in the same specific structural position as in fluoxetine 
itself (4, 11, 12). 
Chlorimipramine is metabolized into the secondary amine desipramine, 
which was suggested in the past years to be the active drug (13). It is now 
clear that desipramine is just as active as imipramine (and chlorimipramine ), 
and not more active (14). The half-life is 13 ± 3 hours, and 89 to 94% of the 
drug is present, bound to plasma proteins (13). The systemic availability varies 
considerably, due to an extensive first-pass metabolism in man (14 ), which 
occurs in the liver after absorption of the drug in the gut. The active drug (or 
its active metabolite desipramine) penetrates the blood-brain barrier, but 
there is a mean ratio of plasma vs. cerebro·spinal fluid concentration of 30 : 1 
(15). In this last study the authors demonstrated that there is a positive cor-
relation between the level of the cerebro-spinal fluid chlorimipramine concen-
trations and those patients with endogenous depression, who responded well 
to the drug. In the non-responders cerebro-spinal fluid concentrations of the 
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drug were significantly lower, with a much higher plasma-CSF ratio. They 
speculated that this might be explained by significant variation in the unbound 
fraction of chlorimipramine in plasma, as described by Glassman et al. (16). 
Fenfluramine is a serotonin-releaser, enhancing CRF and ACTH release, as 
described by Fuller et al. and Schettini (5, 17, 18). This drug depletes brain 
serotonin stores, and does probably the same in the hypothalamus. The half-
life of the drug is 11-20 hours, and it is for 34% bound to plasma proteins. The 
drug is metabolized into nor-fenfluramine, which is pharmacologically active. 
The biological availability is equal when administered orally or systemically 
(19, 20, 21). It is used in man as an inhibitor of appetite in dosages between 
60 and 120 mg/day. 
It is clear from our experiments with fenfluramine that an increase in 
pituitary ACTH content could be induced, when compared with tumor con-
trols, but to a lower level than that found in normal controls. Fenfluramine 
could not completely overcome the suppression of pituitary ACTH content 
in tumor-bearing animals, not even at higher dosages. The increase of ACTH 
release from the pituitary gland was also less pronounced than the one ob-
served after chlorimipramine. Moreover, some experiments, comparable as to 
the dosage used and time period of administration of fenfluramine showed 
inconsistent results. So, in this tumor model fenfluramine was not as effective 
as chlorimipramine in overcoming the effects of high circulating corticosterone 
levels on pituitary ACTH content. 
Piperidine chloride was the third pharmacological agent able to raise the 
pituitary ACTH content and to stimulate ACTH release in vitro. This com-
pound is a nicotinic cholinergic receptor stimulator, which was recently re~ 
ported to enhance sleep-related and insulin-induced growth hormone secretion 
(6), thus establishing a cholinergic mechanism on the control of growth 
hormone secretion. We used piperidine in our experiments considering the 
stimulative role of cholinergic neurons on the release of CRF. A complete 
normalization of the pituitary ACTH content, as found in chlorimipramine-
treated tumor-bearing rats, was not observed after piperidine treatment. This 
might indicate that in the dosages used, piperidine is less potent in stimulating 
CRF release than chlorimipramine. 
Piperidine is normally present in the brain and cerebro-spinal fluid (23). It 
can be produced by a decarboxylase in the brain from pipecolic acid, an 
intermediate of lysine metabolism (24, 25). Piperidine concentrations increase 
in sleeping mice (26 ), while sleep-inducing effects of piperidine have been 
noted in the cat, but not in man (27, 28). The endogenous nicotinic choliner-
gic receptor stimulation of piperidine was first noted by Euler (29) and Abood 
(30). The compound passes easily the blood-brain barrier, especially in the 
mesencephalon, where concentrations of the compound are found which are 
even higher than in the blood, indicating a local synthesis (31). 
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Carbachol, CDP-choline and pyridostigmine had no apparent influence on 
the pituitary ACTH content of tumor-bearing rats. These compounds are all 
cholinergic agents, the latter an anticholine esterase agent. It is not quite 
clear why these drugs failed to exert a stimulating influence on ACTH syn-
thesis. Carbachol and CDP-choline pass the blood-brain barrier in man (32, 33, 
34) and have strong muscarinic agonist properties (35). We used doses of 
drugs comparable with those used in studies mentioned above. The half-life 
of these compounds is relatively short. Perhaps administration should have 
been done more frequently and divided over the day. 
lii.E. CONCLUSIONS 
In summary, we were able to demonstrate that two pharmacologic agents with 
distinct serotonin stimulating actions, chlorimipramine and fenfluramine, can 
stimulate the synthesis in vivo, and the release in vitro of ACTH from the 
anterior pituitary. Even more important is the observation that these drugs 
do so in the simultaneous presence of high circulating glucocorticoid con-
centrations, induced by the ACTH secreting tumor 7315a. Chlorimipramine is 
even capable of preventing the suppression of ACTH synthesis completely. 
Chlorimipramine is thought to act as a "neurotransmitter", stimulating sero~ 
tonergic actions on the CRF neuron, and thus stimulating ACTH synthesis and 
secretion. Fenfluramine is less potent than chlorimipramine in producing this 
effect. Of the four cholinergic stimulating agents tested, only piperidine was 
capable to produce an increase in pituitary ACTH synthesis and release in 
vivo. Our results confirm the importance of serotonergic pathways in the 
control and stimulation of CRF and ACTH release, as stressed by Fuller et al. 
(4) and Buckingham et al. (36). One might speculate on the mutual balance 
of the serotonergic and cholinergic pathways in regulating the activity of the 
hypothalamo-pituitary-adrenal axis: in this tumor model the serotonin de-
pendent pathway can be manipulated much more effectively and the cholinergic 
pathway seems to be of minor importance. 
The results of the administration of chlorimipramine and fenfluramine in 
rats with high circulating corticosterone levels made us wonder whether similar 
actions may be observed in man, receiving high doses of glucocorticoids. Data 
on this question will be presented in the fifth chapter of this thesis. 
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Chapter IV 
Effects of short-term administration of 
glucocorticoids on hypothalamo-pituitary-adrenal 
function in man 
IV.A.INTRODUCT!ON 
The suppressive effect of the administration of glucocorticoids for prolonged 
periods on the activity of the HPA-axis in man has been demonstrated con-
vincingly (see chapter 1). There is, however, little information regarding the 
effect of the administration of glucocorticoids for a relatively short period, 
for example 7-15 days. in one of the few well-documented studies, Streck and 
Lockwood (1) demonstrated a suppression of the HPA-axis in man after the 
administration of 30 mg prednisone per day for I 0 days. 
We wanted to investigate whether this impairment in the activity of the 
HP A-axis occurs in all individuals, after the administration of glucocorticoids 
in pharmacological doses for a short period. Moreover, such a suppression of 
the reactivity of the HP A-axis could have implications for patients, receiving 
glucocorticoids for a short period because of diagnostic tests or for therapeutic 
reasons. At present it is generally advised to supplement only those patients, 
who have been treated with glucocorticoids for periods of several weeks or 
more, with high doses of cortisol, in case of planned stressful diagnostic or 
therapeutic procedures. This is done in order to prevent adrenocortical 
insufficiency (2, 3). Thus, the demonstration of a suppression of the HPA-
axis in patients after short-term glucocorticoid administration might have 
similar implications. 
Clinically there are very few circumstances in which this question can be 
investigated properly. Patients with established hypercalcemia have to go 
through many diagnostic procedures to elucidate the etiology of their elevated 
serum calcium levels (4, 6). Primary hyperparathyroidism is a frequent cause 
of hypercalcemia in man. To discriminate between primary hyperparathyroidism 
and other causes of hypercalcemia, like sarcoidosis and malignancies, pharma-
cological doses of glucocorticoids may be used (prednisone 30 mg/day, during 
10 days) (5). In primary hyperparathyroidism serum calcium remains con-
stant during the course of glucocorticoid administration, whereas the other 
causes of hypercalcemia are characterized by a marked decrease or normal-
ization of serum calcium level during that period. Thus, we used the admin-
istration of glucocorticoids in patients with suspected primary hyperpara-
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thyroidism to investigate the effects on the HP A-axis, and on cortisol levels 
during the stress of a subsequent neck exploration for removal of one or more 
enlarged parathyroid glands. 
IV. B. METHODS AND PATIENTS 
We studied 6 patients with hypercalcemia, who were thought to have primary 
hyperparathyroidism in view of an elevated serum calcium, and a lowered 
serum phosphate level, decreased renal tubular transport of phosphate and 
typical abnormalities in the bone biopsy (6). The age of the patients {2 males, 
4 females) ranged from 47 to 69 years. The HPA-axis was studied using ACTH-
stimulation and metyrapone administration. 
In the case of the ACTH stimulation test, an indwelling needle was placed 
in a suitable vein of the forearm, while patients were in bed to avoid stress. 
45 Minutes after insertion of the needle blood samples for cortisol determination 
were drawn at 30, 15 and 0 min. before administration of ACTH. Synthetic 
ACTH 1 _ 24 (CortrosynR, Organon, Oss), 0.25 mg in 2 ml was then injected 
intravenously, and samples were drawn after 30, 60 and 90 min. The mean 
maximal increment of cortisol after ACTH amounted to 494 ± 31 in 10 normal 
individuals with a range between 405 and 597 nmol/l. Normal basal plasma 
cortisol levels at 15.00 hr amounted to 213 ± 28 (129-359 nmol/l) in 10 
controls. A maximal increment of cortisol after ACTH of more than 195 
nmol/1 is considered to be evidence of normal adrenocortical function. All 
ACTH stimulation tests were performed at 15.00 hour. 
Metyrapone (MetopironR, Ciba) was given orally in a dose of750 mg every 
4 hours for 24 hours, starting at 08.00 hour. After 24 hours, at 08.00 hour the 
following day a blood sample was drawn by venous puncture for determination 
of the plasma desoxycortisol concentration. 
Plasma desoxycortisol concentrations after the administration of metyrapone 
were measured in 43 normal individuals. The levels were higher than 350 
nmol/1 in 36 normal individuals, and between 230 and 350 nmol/l in 7 normal 
individuals and never less than 230 nmol/l. Therefore values between 230 
and 350 nmol/1, are considered to be borderline normal. The ACTH stimulation 
test and the administration of metyrapone preceded the administration of 
glucocorticoids with 2 resp. 1 day. Prednisone (3 X 10 mg/day) in tablets 
of 5 mg was given during 10 days. At day 1 ,2,3,5,7 ,9 and I 0 blood samples 
were drawn for measurement of serum calcium, phosphate, and cortisol at 
08.00 hour. One day after stopping prednisone, at 15.00 hour, the ACTH 
stimulation test was repeated. The next day, again a metyrapone test was 
performed. 
The following day (3 days after termination of prednisone administration) 
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all patients whose tests pointed to the diagnosis of hyperparathyroidism under-
went an operation to explore the size and aspect of the parathyroid glands. 
All operations were scheduled to start at 08.00 hour. Anesthesia was uni-
formly initiated in all patients by the administration ofpenthothal. fentanyl, and 
pavulon. N02 /0 2 gas mixtures, and ethrane were used during anesthesia. 
During operation blood pressure was recorded at 15 min. intervals. Before 
induction of anesthesia, a separate indwelling needle was placed in a suitable 
vein to obtain blood samples during the operation and thereafter. Samples 
for cortisol determination were drawn at 08.00, 08.30, 09.00, 09.30, 10.00, 
10.30 and 11.00 hour. Finally, a third ACTH stimulation test was performed 
I day post-operatively at 15.00 hour. A schematic diagram of the whole 
protocol is shown in figure IV-I. 
As a control group, patients were studied in whom a single, non-cystic, 
"cold" nodule in the thyroid gland was diagnosed. To exclude malignancy, 
these patients underwent exploration of the thyroid, an operation com-
parable with the one in the former group. 7 Patients (7 females) in age ranging 
from 33 tot 67 years, were studied. Anesthesia was carried out in the same 
manner as in the group of patients with primary hyperparathyroidism. Blood 
pressure was measured at 15 min. intervals. During the operation blood samples 
were drawn at the same time intervals as in the first group of patients. 
Cortisol was measured using a radioimmunoassay using the kit supplied by 
Clinical Assays (Cambridge, MA.) ll-Desoxycortisol was measured by radio-
immunoassay after extraction, using the procedure, described earlier for the 
estimation of oestradiol (7, 8) but without chromatography. All patients 
gave informed consent to perform the various procedures. All data are ex-
pressed as mean ± S.E.M. Statistical analysis of data was performed with 
Student's paired t-test, or analysis of variance. 
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Fig. JV-1. A schematic diagram of investigation of the HPA-axis in six patients with 
suspected primary hyperparathyroidism. 
64 
IV.C. RESULTS 
IV.C.!. ACTH stimulation tests and metyrapone tests 
The results of three consecutive ACTH stimulation tests showed an unex-
pected pattern. In Fig. IV -2 plasma cortisol levels are shown at 0 min. (15 .00 h) 
in the six glucocorticoid treated patients, before, immediately after the 10 
day-course of prednisone, and one day after the parathyroid exploration. 
Before prednisone administration the cortisol levels showed a marked variation; 
the values were found to range from 52 tu 510 nmol/1 (mean 245 ± 70 nmol/1). 
Immediately after conclusion of the prednisone course variations in plasma 
cortisol concentrations were much less pronounced (mean 17 6 ± 17 nmol/1). 
In three patients the basal plasma cortisol levels before ACTH administration 
were decreased after the prednisone administration, but in contrast, in three 
others a slight increase was noted at the same time. Overall there was no 
significant change in basal plasma cortisol values before and after prednisone 
administration. However, in 5 patients, pre-ACTH plasma cortisol levels, I day 
after operation, were significantly higher than those immediately after the 
prednisone course (mean 280 ± 29 vs. 176 ± 17 nmol/1; p<0.05). 
Thereafter the maximal increment of plasma cortisol (= llcortisol = highest 
level of cortisol minus basal level) after ACTH stimulation was investigated. 
After the administration of prednisone, a sharp fall in the maximal increment 
of cortisol after ACTH was demonstrated in all patients, when compared with 
llcortisollevels before prednisone (mean 184 ± 25 vs. 511 ± 137 nmol/1 resp.; 
p<0.05; Fig. IV-3). In the six patients llcortisol levels before prednisone 
ranged from 268 - 1152 nmol/1; after prednisone administration the llcortisol 
level ranged from 94- 272 nmol/1. In four of these patients it did not exceed 
the 195 nmol/1 (llcortisol94, 153, 165 and 185 nmol/1), which is considered to 
represent the lower limit of normal. The mean fall in llcortisol was 64.0% in 
comparison with the values before prednisone. One day after operation llcortisol 
levels were significantly elevated, in comparison with the maximal increment 
of plasma cortisol after ACTH immediately after the prednisone course (mean 
574 ± 77 vs. 184 ± 25 mnol/1 resp.; p<0.02; Fig. IV-3). Thus, both basal 
cortisol levels and the maximal increment of cortisol after ACTH were sig-
nificantly higher one day post-operatively than immediately after the gluco-
corticoid period. Furthermore, the llcortisol level after operation was not 
significantly different in comparison with the pre-prednisone llcortisollevels 
(mean: 574 ± 77 vs. 511 ± 137 nmol/1; n.s.; Fig. JV-3 and 4). No alteration 
was found in the basal cortisol levels before prednisone and one day after 
operation (Fig. IV-4). 
The results of metyrapone administration in the 6 patients with primary 
hyperparathyroidism are shown in Fig. IV-5. After administration of mety-
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Fig. IV-2. The effect of the administration of prednisone (30 mg/day for 10 days) on 
basal plasma cortisol levels at 15.00 hour before ACTH stimulation (0 min.), before 
prednisone, 1 day after withdrawal of prednisone, and one day after operation. (-- -- -) 
represent mean values. 
* p<O.OS. 
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Fig. IV-3. The maximal increment of plasma cortisol levels in response to ACTH (Llcortisol) 
before prednisone, 1 day after withdrawal of prednisone, and one day after operation. 
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Fig. IV-4. A comparison of plasma cortisol levels at 15.00 hour (0 min. and Acortisol) 
before prednisone treatment and one day after operation. (--- -) represent mean values. 
rapone 6 X 7 50 mg/24 hours for the first time, a value of desoxycortisol of 
more than 350 nmol/1 was reached in al16 patients. In all6 patients the plasma 
desoxycortisol concentration after metyrapone was reduced markedly after 
the period of glucocorticoid administration. The mean plasma desoxycortisol 
value after metyrapone was 672 ± 99 nmol/1 before, and 389 ± 68 nmol/1 
(p<0.02) after prednisone. 
The cortisol values, at 08.00 hour, during lO days of administration of 
prednisone 3 X 10 mg/day in the six patients are plotted in Fig. IV-6. The 
mean cortisol level at day I was 270 ±51 nmol/1, but it was 135 ± 29 nmol/1 
at day 10 (p<0.05). Thus a decrease in mean cortisol levels of 135 nmol/l was 
found after I 0 days of glucocorticoid administration. The mean cortisol levels 
did not exceed I 75 nmol/1 from day 3 on to reach a nadir at day 10. 
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Fig. IV-6. Plasma cortisol levels at 08.00 hour during prednisone treatment (30 mg/day, 
for 10 days). 0---- -0 represent mean plasma cortisol levels. Mean plasma cortisol levels 
at day 10 vs. mean plasma cortisol level at day 1: p<O.OS. 
IV.C.2. Plasma cortisol levels during operation 
The cortisol values of the prednisone-treated patients during the period of 
induction of anesthesia, operation, and recovery, from 08.00 till 11.00 hour, 
are summarized in Table IV-I. The mean cortisol levels showed a tendency to 
fall from 405 ± 39 at 08.00 to a nadir of 284 ± 56 nmol/1 at 09.30 hour 
(n.s.); thereafter a gradual increase was found to 586 ± 125 nmol/l at 11.00 
hour. In patient 1 ,2,3,4 a parathyroid adenoma was found between 09.00 -
10.00 hour. Anesthesia was ended in these patients at about 10.00 hour. The 
stress of extubation and the recovery from anesthesia caused the plasma 
cortisol to rise markedly. During the time, that was spent in the recovery room 
till 11.00 hr., the cortisol levels rose even further in patients 2,3,4. In patient 
5 a parathyroid adenoma was eventually found in thymic tissue, just above 
the aortic arch, at 11.00 hour. From 09.30 to 10.30 hour hypotension was 
induced by ethrane to prevent capillary bleeding in the operation field. With 
induction of this hypotension the plasma cortisol rose from 210 to 495 nmol/1, 
maintaining a plateau till the end of this procedure (Fig. IV-7). 
Patient 6 underwent a second exploration of the parathyroid region, after 
an unsuccessful operation in another hospital. It was anticipated that the 
adenoma was located in the anterior mediastinum, as angiography of this area 
showed a blush of contrast dye, suggesting a tumor. In this patient the same 
pattern in plasma cortisol levels was observed as in patients 2, 3 and 4: after 
Table IV-I. Plasma cortisol levels of six patients with primary hyperparathyroidism during operation 
Plasma cortisol (nmol/1) 
Time (hours) 08.00 08.30 09.00 09.30 
Patient 1 370 360 430 243 
2 483 451 
3 523 307 353 375 
4 425 246 348 250 
5 250 218 210 495 
6 378 244 216 159 
X 405 304 311 284 
S.E.M. 39 36 43 56 
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Fig. IV-7. Plasma cortisol levels in a patient with hyperparathyroidism during neck ex-
ploration. 
an initial nonmallevel of cortisol at the induction of anesthesia, plasma cortisol 
fell to lower levels ranging from 250 - I 50 nmoljl. From the start of the 
procedure of sternotomy, plasma cortisol rose sharply, reaching a value of 
516 nmol/l at 10.30 hour, at which time the severed sternum was closed with 
traction. The cortisol level rose even further to 767 nmol/1 during the re-
covery from anesthesia, at I 1.00 hour (Fig. IV-8). In all six patients a para-
thyroid adenoma was found and proven histologically. 
The plasma cortisol concentrations of seven patients with a single cold 
nodule in the thyroid, undergoing a thyroid exploration, are shown in Table 
IV-ll. 
The control patients, who underwent exploration of the thyroid region 
showed a similar pattern of plasma cortisol levels, as the one observed in the 
prednisone treated patients. The total operation time of the thyroid exploration 
ranged from 90 min. to 3 hours, and was thus comparable with the duration 
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Fig. IV-8. Plasma cortisol levels in a patient with hyperparathyroidism during neck ope-
ration. 
of parathyroid exploration. In the control group a similar and sharp increase 
in the plasma cortisol concentration was seen after 09.00 hour, which rose to 
even higher levels at 10.00 hour and later, representing the recovery of anesthesia 
and the period spent in the recovery room. The mean cortisol levels rose from 
488 nmol/1 at 09.00 hour to a maximum of931 runol/1 at 11.00 hour. Between 
the induction of anesthesia at 08.00 hour and 09.00 hour the mean levels 
fluctuated between 468 and 534 nmol/1. Patient F, a female of 66 years old, 
presented very high plasma cortisol values throughout the whole duration of 
the thyroid exploration, which took 2)6 hours (levels fluctuating between 
954-1353 nmol/1). She did not have signs of hypercortisolism at clinical or 
biochemical examination. 
Table IV-II. P!a1.ma cortisol levels of seven patients with a "cold" thyroid nodule, serving as controls, during operation 
Plasma cortisol (nmol/1) 
Time (hours) 08.00 08.30 09.00 09.30 10.00 
Patient A 630 425 347 239 215 
B 213 255 289 336 369 
c 667 667 543 811 505 
D 304 278 300 1053 1384 
E 308 791 899 1126 1203 
F 1041 1231 954 1209 1109 
G 111 93 81 834 1418 
X 468 534 488 801 886 
S.E.M. 123 147 124 143 191 
10.30 
297 
472 
822 
1080 
1044 
1240 
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879 
139 
11.00 
681 
472 
862 
1079 
1177 
1353 
__, 
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Patient G on the other hand, showed remarkably low cortisol levels at the 
beginning of the operation, ranging from 111 nmol/1 at 08.00 hour to 81 
nmol/1 at 09.00 hour. At 09.30 hour, the moment of removal of a part of the 
thyroid gland, containing the cold nodule, cortisol levels rose sharply to 
834 nmol/1, and even higher to 1418 and 1200 nmol/1 at the period of re-
covery from anesthesia. A comparison of the mean cortisol values found in the 
patients who had received prednisone before operation, and those of the 
control group is made in Fig. IV-9. All mean values in the prednisone treated 
group were below those of the controls, at all times of study. Especially from 
09.30 hour on the two lines diverged significantly (p<0.05). When the areas 
under both curves are compared, the area under the curve representing the 
plasma cortisol values of glucocorticoid treated patients is significantly smaller 
than that of the controls (p<O.OS). The mean maximal increment of plasma 
cortisol from 09.00- 09.30 till I 1.00 hour amounted to 251 ± 127 nmol/1 in 
the group of hypercalcemia patients and to 443 ± 94 in the thyroid patients. 
This difference is significant (p<0.05). 
The clinical events during and after operation were not different between 
the 6 prednisone treated patients and the 7 control patients. No complications 
or signs and symptoms which could be related to (relative) adrenocortical 
insufficiency were noted. Blood pressure in the period before, during and 
in the first 24 hrs after operation were also not different between both groups 
of patients. 
lV.D. DISCUSSION 
From this study it is clear that the short-term effect of glucocorticoids on the 
HP A-axis is pronounced. The results of the administration of metyrapone, 
which assesses the integrity of responsiveness of the HPA-axis, demonstrates 
an impairment of the reactivity of the HPA system after 10 days of pred-
nisone administration. A similarly lowered responsiveness of the adrenal 
cortex to ACTH was shown in these patients. 
Abnormalities in the response of the HP A-axis to metyrapone and ACTH 
testing were reported by Plager (9) to occur after 3 days of glucocorticoid 
treatment (cortisol 100 mg/day). Christy found an impairment of the axis 
after similar short treatment periods (10). On the other hand, Treadwell et 
a!. (I 1), using metyrapone, could only find an abnormal response if patients 
were treated for more than 15 months. It must be noted, however, that most 
of their patients took lower doses of prednisone (15 mg or less) than in our 
study and the other reports quoted. 
When we interpret the data obtained in the three consecutive ACTH sti-
mulation tests, it is clear that the administration of glucocorticoids for I 0 days, 
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F'ig. JV-9. Plasma cortisol levels (mean± S.E.M.) of 6 patients with primary hyperpara-
thyroidism (pretreated with prednisone)(---) and of 7 patients with a "cold" thyroid 
nodulle, serving as controls, who underwent a similar neck exploration (---- -). 
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impairs the adrenocortical response to ACTH significantly. Especially the 
maximal secretory capacity of the adrenals (represented by L\cortisol) was 
decreased after 10 days of prednisone in all patients. Basal plasma cortisol 
levels at 15.00 hour (immediately before ACTH administration) were not 
lowered after 10 days of prednisone, although plasma cortisol levels at 08.00 
hr. were statistically significantly suppressed (Fig. IV-6). This could be caused 
partly by the fact that the diurnal rhythm of plasma cortisol before prednisone 
resulted in relatively low levels at 15.00 hour, while it is well known that 
differences in "internal" stress, as anxiousness and tensions are able to cause 
marked variations in the plasma cortisol concentration. This wide variation in 
basal plasma cortisol levels makes clear, oncemore, how little information 
with regard to the integrity and responsiveness of the HPA-axis can be de-
ducted from single plasma cortisol determinations. 
lt is possible to determine from our data the duration of suppression of the 
HP A-axis. The basal plasma cortisol levels, and the maximal response to ACTH 
were completely normalized one day after the operation, that is, five days after 
the end of the course of glucocorticoid administration. However, one should 
bear in mind, that in these tests a supraphysiological concentration of ACTH 
is used, forcing the adrenals to secrete cortisol to the maximum of their ca-
pacity. It is uncertain whether under these circumstances physiological con-
centrations of ACTH, secreted by the anterior pituitary gland, are able to meet 
the needs for cortisol of the bodies homoiostasis. As will be discussed later, the 
levels of plasma cortisol concentrations obtained during the operation indicate 
that they are not. Combining the results of metyrapone and ACTH stimulation, 
we demonstrated that the response of the HPA-axis was still impaired three 
days after cessation of the glucocorticoids, but was normal again after five 
days. Thus, the recovery was completed between the third and fifth day. As 
demonstrated by Graber (12, see chapter I, Fig. 1-l), ACTH secretion recovers 
before the cortisol release. This does not necessarily mean that the HP A-
system is completely normal when there is a normal respons on ACTH sti-
mulation, taking into account the high dosage of ACTH used. The metyrapone 
stimulation gives more accurate information on the integrity of the hypo· 
thalamo-pituitary, and pituitary-adrenal responses (13, 14, 15, 16, 19). Further-
more, we found a significant rise both in the basal and maximally stimulated 
plasma cortisol levels, one day postoperatively when compared with those 
immediately after cessation of the prednisone, indicating a recovery of adrenal 
function (17, 20, 21, 22). 
It is interesting to see that, although responses of plasma cortisol to ACTH 
testing were normal one day later, the cortisol1evels one day earlier (on the day 
of operation) were significantly lower in the glucocorticoid treated patients, 
when compared with the controls. At all times measured, the plasma cortisol 
levels were lower in the first group. In both groups the patterns of the cortisol 
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levels were similar during the total period of observation. At 08.00 hour, when 
the general anesthesia was induced, the cortisol levels were normal (400 -
475 nmol/1), indicating a stress factor to the patient. During the actual surgery 
plasma cortisol levels fell in the glucocorticoid treated patients until 09.30 
hour. This indicates that this period was relatively little stressful (18). 
In patient 5, whose blood pressure had to be controlled with induced 
hypotension, an immediate rise of the cortisol level was found, indicating the 
response of a well known control mechanism (23). The patient, undergoing a 
reexploration of the cervical area with sternotomy, showed a very impressive 
rise of plasma cortisol levels, in particular when the sternum wound was closed 
with forceful traction on the steel sutures. Although both groups of patients 
demonstrated a sharp rise in cortisol levels after the end of the operation, 
during termination of the general anesthesia, and during the period they spent 
in the recovery room, it is clear from the divergence of both lines in Fig. IV-9 
that in the control group the adrenals were able to produce much more cortisol 
than those in the glucocorticoid treated group. Thus, from this figure it can be 
concluded that prednisone administration impaired the responsiveness of the 
adrenals in their maximal secretory capacity. The suppression, which was 
found immediately after withdrawal of the glucocorticoids was still to some 
extent present at the fourth day, after stopping. On the fifth day, however, a 
normal respons of cortisol to ACTH stimulation was found. 
Several authors (Jasani et al. (23), Kehlet et al. (24), Marks et al. (18) and 
Sampson et al. (25)) have reported on possible correlations between responses 
of the HP A system and plasma cortisol levels during induction of general 
anesthesia and operations, in patients previously or simultaneously treated 
with pharmacologic doses of glucocorticoids. Investigating the HPA responsive-
ness with a short-term ACTH stimulation test (plasma cortisol levels 30 min. 
after the intravenous injection of 0.25 mg ACTH), Jasani et al. found a cor-
relation between the maximal response of plasma cortisol levels after ACTH 
and the maximal cortisol levels during operations. When the HP A system was 
tested, using prolonged infusion of ACTH during 6 hours, a similar correlation 
between the maximal rise in cortisol levels and the levels of cortisol during 
anesthesia and surgery was found (18, 25). In other words, one might expect 
normal reactions of the HP A system, at stressful periods, in glucocorticoid 
treated patients, when a previous ACTH testing was normal. In our results the 
responsiveness of the HP A-axis was less than that of the normal control group, 
as might be expected by the previous abnormal responses on ACTH and 
metyrapone testing. 
Although we did not observe signs of circulatory collapse in any of the 
glucocorticoid treated patients, these results indicate that even after such a 
short period of glucocorticoid administration (relative) adrenocortical in-
sufficiency might occur. Thus, anesthesiologists and physicians should be 
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aware of this potential hazard, and consider appropriate actions, like the 
supplemental administration of glucocorticoids (13). 
Jasani et al. {14, 26) demonstrated that a normal response of cortisol to 
ACTH stimulation does not imply normal reactivity to metyrapone, insulin· 
induced hypoglycemia or lysine-vasopressin. To assess the HPA integrity more 
accurately the use of both ACTH stimulation and metyrapone testing may be 
advocated. 
In summary, we demonstrated a suppression of the hypothalamo-pituitary-
adrenal system after a short period (10 days) of glucocorticoid administration 
in pharmacologic dosages. Immediately after the withdrawal of the gluco· 
corticoids, both ACTH stimulation and metyrapone testing showed an im· 
paired response, indicating a substantial influence on the HPA system. 
This impairment in the response was present for 3-4 days; thereafter a 
normal responsiveness of the adrenal part of the HPA system was found again. 
During a period of prolonged stress (induction of general anesthesia, surgery, 
reversal of anesthesia, and the post-operative period) the secretory capacity of 
the adrenals was impaired in the glucocorticoid treated patients, when com-
pared with a control group, undergoing a similar stressful procedure. 
These data suggest that even after short courses of glucocorticoids the 
occurrence of adrenocortical insufficiency is a real possibility and that the 
deleterious effects of these drugs can be serious. 
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Chapter V 
Effects of chlorimipramine: a drug with possible 
serotonin enhancing effects on the glucocorticoid 
mediated suppression of the HPA-axis, in man 
V.A. INTRODUCTION 
The aim of this study was to investigate whether it is possible to prevent the 
negative effect of glucocorticoids on the HP A-axis in man. We wanted to 
know whether drugs, which are known to stimulate ACTH secretion are able 
to prevent partially the suppressive effects of glucocorticoids on pituitary-
adrenal function. In the previous chapter (chapter IV) we demonstrated the 
profound suppressive effects of short-term glucocorticoid administration on 
the HP A-axis. In chapter Ill it was shown that chlorimipramine, a pharma-
cological agent with serotonin enhancing effects on CRF release was capable 
to prevent in rats the suppression of the pituitary ACTH release and content 
which was induced by a transplantable ACTH secreting pituitary tumor. In 
this chapter the effects of the chronic administration of chlorimipramine are 
described on the prednisone-induced suppression of HPA-function in patients 
with suspected hyperparathyroidism. 
V.B. METHODS AND PATIENTS 
Six patients with hypercalcemia, who were suspected to have primary hyper-
parathyroidism were asked to participate in the study. The same criteria (as 
mentioned in chapter IV) were applied to make the diagnosis of hyperpara-
thyroidism probable. The ACTH stimulation test and the metyrapone sti-
mulation test were performed as described in the previous chapter. Exactly the 
same protocol was followed as described (Fig. IV-1) for the study of the effect 
of prednisone on the HP A-axis in the hypercalcemic patients. However, after 
the completion of the first ACTH and metyrapone stimulation tests, chlorimi-
pramine was administered together with prednisone. Prednisone 10 mg (in 
tablets of 5 mg) was given three times a day during 10 days. Chlorimipramine 
(AnafranilR, Geigy) was given orally in tablets of 25 mg. On the first and 
second day of the prednisone administration chlorimipramine was given in a 
dose of 2 X 25 mg; on the third day in a dosis of 3 X 25 mg; from the fourth 
until the tenth day in a dose of 4 X 25 mg a day. Thereafter the study was 
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completed in accordance with the protocol described earlier in detail. Again, 
all patients, in whom the diagnosis of primary hyperparathyroidism was made, 
underwent exploration of the parathyroids, three days after completing the 
combined drug regimen. One patient was not operated upon because the 
serum calcium level normalized after prednisone administration. The operation 
and anesthesia were performed as described earlier (chapter IV). All six patients 
(1 male, 5 females) in age ranging between 45 and 50 years, gave written in-
formed consent. Data are expressed as mean ± S.E.M. Statistical analysis of the 
data was performed with Student's paired t-test, or analysis of variance. 
V.C. RESULTS 
V.C.l. Effects of chlorimipramine on ACTH-and metyrapone stimulation tests 
The results of the consecutive ACTH stimulation tests are shown in Fig. V-1. 
In one patient an ACTH stimulation test could not be repeated on the day 
after the operation. The plasma cortisol levels at 0 min., before ACTH ad-
ministration, did show a significant decrease when values before prednisone/ 
ch.lorimipramine administration were compared with values after conclusion 
of the drug regimen. The cortisol levels before ACTH varied from 167 to 315 
nmol/1 (mean 249 ± 25 nmol/1) in the ACTH stimulation test, which was 
performed before the administration of the drugs. In the second test, after 
stopping the two drugs, plasma cortisol levels at 0 min. varied from 50 to 156 
nmol/1 (mean 104 ± 14 nmol/1). There was a significant fall in mean values at 
0 min. before and after the administration of prednisone and chlorimipramine. 
(Fig. V-1; p<O.O 1 ). Again a significant increase could be demonstrated when 
mean basal cortisol levels after operation were compared with those of the 
ACTH stimulation test, performed after discontinuation of the drugs (mean 
225 ± 32 vs. 104 ± 14 nmol/1; p<0.05; ranges 139- 328; resp. 50- 156 nmol/1; 
Fig. V-1). 
In Fig. V-2 the maximal increment of plasma cortisol (Licortisol) after 
ACTH administration is shown before and after the administration of pred-
nisone and chlorimipramine and one day after operation. After the com-
bined drug regimen the mean value of Llcortisollevels was significantly lower in 
comparison with the one found before drug treatment (mean 273 ± 22 vs. 660 
± 48 nmol/1; p<0.005). The Llcortisol values after drug treatment ranged in the 
six patients from 205 to 368 nmol/1; those found before the start of the drug 
administration ranged from 501 to 791 nmol/1. Thus, all Llcortisol values 
exceeded the lowest normal limit of 195 nmol/1. When the maximal increment 
of cortisol levels after ACTH one day after operation was compared with the 
Llcortisol levels after drug treatment a significant increase was noted. The 
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Fig. V-1. Basal plasma cortisol (nmol/1) before administration of ACTH, prior to treat-
ment with chlorimipramine (2 X 25 mg-"" 4 X 25 mg/day) and prednisone 3 X 10 mgfday, 
after combined drug treatment and 1 day after operation resp. in 6 patients with sus-
pected primary hyperparathyroidism. (e---- e) represent mean values. 
* p<O.O 1 
** p<O.OS. 
values ranged from 396 to 828 {mean 652 ± 72) nmol/1 after operation, vs. 205 
to 368 (mean 273 ± 22) nmol/1 after drug treatment (p<O.O 1; Fig. V -2). The 
basal plasma cortisol levels and the maximal increment of plasma cortisol 
after ACTH did not show significant changes when a comparison was made 
between values before the prednisone/chlorimipramine treatment and values 
one day after operation (basal levels: mean 249 ± 25 vs. 225 ± 32 n.s.;Ll.cortisol: 
660 ± 48 vs. 652 ± 72 nmol/1 n.s.; Fig. V-3). 
The results of metyrapone administration in the patients studied are shown 
in Fig. V-4. In all patients the plasma desoxycortisol concentration after 
metyrapone was decreased when levels after drug treatment were compared 
with levels before treatment: range 323 - 459 (mean 372 ± 25) nmol/1 after 
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Fig. V-2. Maximal increment of plasma cortisol (nmol/1) (.6cortisol) after ACTH sti-
mulation before and after treatment with chlorimipraminc (2 X 25 mg ___, 4 X 25 mg/day) 
and prednisone (3 X 10 mg/day); and 1 day after operation resp., in 6 patients with 
suspected primary hyperparathyroidism (e---- G) represent mean values. 
' p<O.OOS 
** p< 0.01 
------ represent lower limit of normal Acortisol (195 nmol/1). 
drug treatment vs. 491 - 630 (mean 548 ± 9) nmol/1; p<0.05; Fig. V-4. All 
metyrapone stimulation tests showed desoxycortisol values over 350 nmol/1 
after metyrapone in the pre-treatment test. After prednisone/chlorimipramine 
administration desoxycortisol concentrations after metyrapone were over 
350 nmol/1 in 3 patients, and between 230- 350 nmol/1 in the other 3 patients 
(323, 323 and 329 resp.). 
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fig. V -3_ A comparison of basal plasma cortisol level and 6.cortisol after ACTH stimulatJl .... 
before chlorimipramine/prednisone treatment and I day after operation, in 5 patients 
with definite primary hyperparathyrcoidism. (e---- e) represent mean values. 
V.C.2. Effects of prednisonejchlorimipramine compared with prednisone only 
on ACTH- and metyrapone stimulation tests 
We compared the results of the ACTH stimulation test in the patients, who 
underwent the prednisone/chlorimipramine regimen with the same test in those 
who were treated with prednisone only, after completing the respective drug 
regimen. In Table V-1 the plasma cortisol levels at 0, 30, 60 and 90 min., mean 
values, and mean [\cortisol levels of the ACTH stimulation tests in the two 
groups of patients are shown together. The mean basal plasma cortisol levels 
in all three ACTH stimulation tests did not differ significantly in either group. 
The mean values before drug treatment amounted to 245 ± 70 nmol/l in the 
group treated with prednisone only versus 249 ± 25 nmol/1 in the group sub-
mitted to a prednisone/chlorimipramine regimen (n.s.). After the drug treat-
ment those figures were 176 ± 17 nmol/1 vs. 104 ± 14 nmol/1 resp. (n.s.). 
One day after operation a mean basal cortisol value of 280 ± 29 nmol/1 vs. 
225 ± 32 nmol/1 before treatment was found (n.s.). 
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The maximal increment of plasma cortisol (Licortisol) after ACTH ad-
ministration in the patients treated with prednisone and chlorimipramine was 
significantly greater than the Llcortisol value in the patients treated with 
prednisone only; mean 273 ± 22 vs. 184 ± 25 nmol/1 (p<0.05; Table V -1). 
Four of the six patients who were treated with prednisone only showed a sub-
normal response of Llcortisol levels directly after prednisone: 94, 153, 165, 
and 185 nmol/1. In the patients, who received prednisone/chlorimipramine 
treatment, Llcortisol le\els ranged from 205 - 368 nmol/1; mean: 273 ± 22 
Tahle VI. ACTH stimulation tests in 12 patients with primary hyperparathyroidism, after treatment either with prednisone (30 mg/day for 10 days) or 
with chlorimipraminc (2 X 25 mg---+ 4 X 25 mg/day and prednisone 30 mg/day for 10 days) 
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nmol/1, thus in all exceeding the level of 195 nmol/1, which is considered to be 
the lower limit of normal. 
The mean maximal increment of cortisol after ACTH treatment with either 
drug regimen amounted to 660 ± 48 nmol/1 in the group to be treated with 
prednisone/chlorimipramine, as to 511 ± 137 in patients treated with pred-
nisone only (n.s.). 
One day after operation a comparison of the two drug regimes did not show 
a significant change in mean Llcortisollevels (652 ± 72 nmol/1 with prednisone/ 
chlorimipramine vs. 57 4 ± 77 nmol/1 with prednisone only; n.s.). The decre-
ment of Llcortisol levels was not significantly different when both drug regimes 
were compared. 
Mean desoxycortisol levels before the drug administration were 548 ± 9 
nmol/1 in the "chlorimipramine" group, as to 672 ± 99 nmol/1 in the "pred-
nisone" group (n.s.). Mean desoxycortisol concentration after prednisone/ 
chlorimipramine was 372 ± 25 nmol/1, while this concentration amounted to 
389 ± 68 nmol/1 after prednisone treatment only (n.s.). Two patients in the 
latter group did have desoxycortisol concentrations after metyrapone ad-
ministration which were abnormal (both 211 nmol/1). In one patient this 
value was borderline (344 nmol/1); the others showed normal values. Those 
patients who underwent prednisone/chlorimipramine treatment had a normal 
value in three cases, while the others were at the lower limits of normal (323 
to 329 nmol/1). 
However, when the decrement of desoxycortisol (i.e. desoxycortisol before 
drug treatment minus desoxycortisol after drug treatment) was determined, 
a different pattern emerged: the mean decrement of desoxycortisol in the 
patients treated with prednisone only was 384 ±52 nmol/1 vs. 176 ± 34 nmol/1 
in the patients treated with both prednisone and chlorimipramine (p<O.O!; 
Fig. V-5). 
The cortisol levels at 08.00 hour during 10 days of administration of pred-
nisone and chlorimipramine are shown in Fig. V-6. Again a decrease in mean 
cortisol levels was noted from 324 ± 69 on day I to 170 ± 34 at day 10 
(p<0.05). There was no significant difference when the figures found in 
patients treated with prednisone/chlorimipramine were compared with the 
corresponding ones in those treated with prednisone only, neither on day 1 nor 
on subsequent days till day 10. 
V.C.3. Plasma cortisol levels during operation 
The plasma cortisol levels in the prednisone/chlorimipramine treated patients 
demonstrated from the start of anesthesia till the recovery period a pattern 
similar to the one found in patients treated with prednisone only. After initial 
high levels (mean 392 ± 70 nmol/1 at 08.00 hour) the plasma cortisol levels 
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Fig. V-5. Mean decrement of desoxycortisol (nmol/1) after metyrapone administration, 
after treatment with prednisone (open bars) and after treatment with chlorimipraminc 
and prednisone (hatched bars). 
* p<O.Ol. 
decreased to a lowest level of 234 ±59 at 09.30 hour. Thereafter mean cortisol 
le;els increased again to a maximum of 407 ± 117 nmol/1 at 11.00 hour. 
There were no significant differences in mean plasma cortisol levels between 
both patient groups at any time (Fig. V-7). The results of 5 patients who 
underwent surgery of the parathyroid region are summarized in Table V-11. 
As mentioned before, in the sixth patient surgery had to be postponed be-
cause the plasma calcium level normalized on the day of the scheduled operation. 
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Fig. V-6. Plasma cortisol levels (nmol/1) at 08.00 hours during 10 days of treatment with 
chlorimipramine/prcdnisone in 6 patients with suspected primary hyperparathyroidism. 
(e--- -e) represent mean plasma cortisol. 
During and after operation there were no obvious signs which might point 
to (relative) adrenocortical insufficiency: there were no important changes in 
blood pressure or heart rate. All patients recovered uneventful from operation 
and anesthesia. In this series of patients it was not necessary to induce hypo-
tension during the operation at any time. 
V.D. DISCUSSION 
From the data reported certain conclusions can be drawn. It is clear that after 
administration of prednisone 30 mg/day combined with an increasing dose of 
chlorimipramine (50 -> 100 mg/day) a significant impairment in responsiveness 
of the HPA-axis is still found. Addition of chlorimipramine in the doses used 
could not prevent tilis impairment. However, there are certain positive effects. 
Four of six patients showed an insufficient reaction of plasma cortisol to 
ACTH stimulation after administration of prednisone 30 mg/day, when related 
to the lower limit of normal of 195 nmol/1. In contrast all six patients, to whom 
chlorimipramine and prednisone had been given, had a normal response to 
ACTH stimulation. This suggests that the responsiveness of the adrenal cortex 
to ACTH stimulation was improved in the latter group. Moreover, the mean 
maximal increment of cortisol levels immediately after treatment with chlor-
imipramine and prednisone, following an ACTH stimulation test was significantly 
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Fig. V-7. Comparison of mean plasma cortisol levels (nmol/l) ± S.E.M. in 6 patients with 
primary hyperparathyroidism after previous treatment with prednisone (30 mg/day, for 
10 days) (---); and in 5 patients with primary hyperparathyroidism after previous 
treatment with chlorimipramine (50-+ 100 mg/day, for 10 days with prednisone 30 mg/ 
day, for 10 days) (- - · - · - ), during parathyroid exploration; 7 patients with a single 
thyroid nodule during neck exploration(------) served as a control group. 
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Tabel V-II. Plasma cortisol levels in 5 patients with primary hyperparathyroidism, during 
surgery, after previous treatment with chlorimipramine and prednisone for 10 days. 
Cortisol (nmol/0 
08.00 08.30 09.00 09.30 10.00 10.30 1LOO (hours) 
1 547 344 324 278 240 278 235 
2 533 462 288 287 335 300 385 
3 165 123 131 82 75 87 83 
4 258 188 156 119 102 406 614 
5 457 342 405 402 695 800 717 
x 392 292 263 234 289 374 407 
S.E.M. 70 56 52 59 112 118 117 
higher than the one found after treatment with prednisone only. This finding 
confirms the suggestion of an improved responsiveness of the "adrenal" part of 
the HP A-axis. 
Desoxycortisol levels after metyrapone stimulation decreased less after 
treatment with prednisone and chlorimipramine than after treatment with 
prednisone alone. There were 2 patients with an abnormal response to mety-
rapone after prednisone treatment, while one was borderline. With chlorimi-
prarnine administration no patient showed an abnormal reaction: in all it was 
normal or at the lower limit of normal. Thus, chlorimipramine seems to im-
prove also the responsiveness of the HPA system to metyrapone. This was 
confirmed further, by the finding of a significantly more pronounced decre-
ment of desoxycortisol levels after treatment with prednisone, when compared 
with the decrement found after treatment with both drugs. So, the respons-
iveness of the whole HP A-axis appears to improve. 
On the other hand we could not demonstrate a significant elevation of 
plasma cortisol levels either during the period ofchlorimipramine administration 
or during operation. 
The results obtained from ACTH and metyrapone stimulation tests seem to 
confirm to some extent our hypothesis regarding the importance of a serotonin 
enhancing effect of chlorimipramine on HPA function. The recovery of the 
hypothalamo-pituitary part of the axis seems to be more pronounced than the 
adrenal part of the axis. lt was not possible to prevent completely a suppression 
of the HPA-axis with this dose of chlorimipramine. The dose which was 
chosen is a moderate one; in psychiatric patients with severe depression higher 
doses are used (I). Moreover, chlorimipramine has to be given in a rising dose in 
order to diminish unwanted side-effects (2). Finally, a plateau in the con-
centration of the active metabolite of this drug is reached only after 2-3 days 
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of administration (1 ,2,3). So the duration of administration was relatively 
short and the maximum dose of chlorimipramine was limited. 
Thirty mg of prednisone (equivalent to 120 mg cortisol) constitute a large 
glucocorticoid potency, and represent at least four times the normal daily pro-
duction of cortisol by the adrenal glands. Moreover, the fact that this dose is 
divided over 3 doses a day causes a constant, 24 hour suppression of the HP A-
axis (4). The extent of suppression of the HPA-axis correlates well with the 
amount of glucocorticoids given (5). Chlorimipramine was able to improve the 
maximal responses of the HPA-axis after stimulation either with ACTH or 
metyrapone (after all, it might be stressed that in those patients who had re-
ceived chlorimipramine together with prednisone no abnormal responses to 
ACTH stimulation and no abnormal responses after metyrapone were observed). 
Thus it seems reasonable to attribute these results to the presumed serotonin 
enhancing actions of chlorimipramine. 
As we discussed in chapter l there is convincing evidence that the recovery 
of the suppression of the HP A-axis originates in the enhanced secretion of CRF 
by the hypothalamus (Graber et al. (6); Buckingham (7)). Therefore we tried 
to prevent suppression of the HPA-axis by stimulating this process of recovery 
in man, in a similar way as we demonstrated in rats (see chapter Ill). 
It is unclear why basal plasma cortisol levels during operation in chlorimi-
pramine treated patients were similar as those observed after prednisone 
alone. When considering the cortisol levels during operation in chlorimipramine 
treated patients, we observe a pattern similar to that observed in prednisone 
treated patients. After moderately high initial levels the plasma cortisol levels 
fell to much lower values, and again (as found before) a nadir was reached at 
09.30 hour. However, cortisol levels during operation in chlorimipramine 
treated patients were not significantly different from those in prednisone 
treated patients. In this case we could not demonstrate an enhancing effect of 
chlorimipramine on the HP A-system. When the cortisol levels at 08.00 hour 
during the administration of chlorimipramine and prednisone are compared 
with the plasma cortisol levels in patients treated with prednisone only, no 
significant increase could be found. Again the profound suppressing effect of 
this dose of prednisone on HP A function seems to prevent an elevation of 
cortisol levels in a basal state. 
V.E. CONCLUSIONS 
The results of this study demonstrate that chlorirnipramine seems to exert 
some positive effects on the HP A function. Chlorimipramine enhances 
the responsiveness of the HP A system as measured by ACTH- and metyrapone 
stimulation tests, but cannot prevent all the suppressive effects of prednisone. 
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In basal states and during a period of stress in anesthesia and surgery, how-
ever, there was no significant rise in cortisol levels in chlorimipramine treated 
patients. We suggest that either lower doses of prednisone or higher doses of 
chlorimipramine over a more prolonged period might show such elevations. 
These results seem to indicate that administration of drugs, which induce a 
serotonin enhancing effect on the hypothalamus might result in the (partial) 
prevention of suppression of the HP A-axis by glucocorticoids. 
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Chapter VI 
General discussion and summary 
The suppressive effects of prolonged administration of pharmacologic doses of 
glucocorticoids on the HP A function are wellknown and often represent a 
major problem in clinical practice: it is unknown after what duration of ad-
ministration, and for what dosages of glucocorticoids precisely suppression of 
HPA function can be expected. 
A review of the literature discloses only a few definite answers to these 
questions as summarized in chapter I. However, it is certain that the HP A-axis 
is defined by a closed loop negative feedback system. The existence of corti-
cotrophin releasing factors (CRF's) has been proved by a large amount of 
"circumstantial" evidence, but the exact nature of the main compound re-
mained uncertain, until the recent isolation and characterization of an ovine 
CRF, which was a polypeptide of 41 aminoacids. It seems very probably how-
ever that other compounds will be detected which also exert CRF-like activity, 
and that not one "universal" CRF can be found. 
The evidence for the existence of a "short" loop negative feedback effect 
of ACTH on CRF release has been reviewed also in chapter !. Most studies 
appeared in the late sixties and early seventies and almost all data were ob-
tained from rats under very special circumstances, and the physiological im-
plications of this phenomenon remained uncertain. 
The importance of neurotransmitters in the synthesis and release of CRF 
has been demonstrated convincingly by many authors. The existence of cholin-
ergic and adrenergic pathways were known for a considerable time. The im-
portance of serotonin as a stimulatory neurotransmitter gained increased 
attention in the last ten years. 
In this study our main aim was to determine whether stimulation of neuro-
transmitter activity with drugs might be able to enhance the HP A function to 
such extent that suppression by high circulating glucocorticoid levels could 
be prevented. 
In chapter ll the model of the transplantable ACTH/PRL secreting tumor 
7315a is described. This model enabled us to study the importance of a postu-
lated "short" loop negative feedback mechanism of ACTH and CRF. We de-
monstrated that the high circulating corticosterone levels were the main factor 
in inducing a negative feedback mechanism on pituitary ACTH synthesis and 
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release. We could not find conclusive evidence for the existence of a "short" 
loop negative feedback mechanism of ACTH on CRF in this model. 
In chapter lll we described our efforts to influence the hypothalamo-
pituitary axis in rats with different drugs with postulated serotonergic or 
cholinergic actions. The manipulation of the hypothalamo-pituitary axis with 
serotonergic drugs was much more successful than cholinergic stimulation. 
Especially chlorimiprarnine was able to prevent suppression of the pituitary 
ACTH content and ACTH release in the simultaneous presence of high cir-
culating corticosterone concentrations. The effects of fenfluramine were less 
pronounced. 
In chapter IV we investigated the effects of relatively high doses of pred-
nisone on the HP A function in man in a prospective protocol. lt was made 
clear that, even when prednisone was administered for such a short period as 
l 0 days, there was an extensive suppression of the HPA-axis in hypercalcemic 
patients. In several patients there was biochemical evidence of adrenocortical 
insufficiency. During surgery the HP A response in those patients was significant-
ly less then in a comparable control group of patients. This indicates that 
stressful procedures may be hazardous even after glucocorticoid administration 
for a short time. On the other hand the recovery of the HPA function was fast. 
One day after operation the adrenal response to ACTH stimulation was com-
pletely normal again. 
Finally, in chapter V we tried to influence the HPA function in a manner 
similar to the experiments in rats, using chlorimipramine simultaneously with 
an identical dose of prednisone as used in the hypercalcemic patients studied 
in the first group. As far as we know, there are no reports in the literature in 
which the HPA-axis in man was manipulated with drugs with presumed neuro-
transmitter (e.g. serotonin) enhancing activity in order to prevent the sup-
pression of HP A function by glucocorticoids. Although the results in rats 
were very promising, those obtained in our patients treated with both drugs 
were less clear. However, no cases of evident biochemical adrenocortical in-
sufficiency were noted after chlorimipramine, as were seen in the patients 
treated with prednisone only. There was a significant improvement in the 
responsiveness of the whole HPA-axis after treatment with chlorimipramine, 
when evaluated with ACTH stimulation and metyrapone testing. 
On the other hand the plasma cortisol levels, neither during the lO days 
period of the combined drug regimen nor during surgery showed differences in 
comparison with those patients treated with prednisone alone. So we were not 
able to prevent with chlorimipramine all suppression of the HPA function 
caused by glucocorticoids. The most probable explanation is that the dose of 
glucocorticoids used, was too high to prevent suppression with this moderate 
dose of chlorimiprarnine. Lower doses of glucocorticoids in combination with 
higher doses of serotonin enhancing drugs as chlorimipramine and may be 
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fenfluramine might yield better and more promising results. This, however, has 
yet to be investigated. Nevertheless, the results of our experiments in rats and 
some of the results in man suggest that the HP A-axis can be influenced by 
modulating neurotransmitter activity with drugs with putative stimulating 
actions on the CRF synthesis and release. 

Sam en vatting 
Het supprimerend effect op de hypothalamus-hypofyse-bijnieras van farmaco-
logische doses glucocorticoiden is algemeen bekend, en vormt regelmatig een 
reeel probleem in de kliniek; in feite is niet goed bekend boven welke doseringen 
en na welke tijdsduur van toediening deze suppressie optreedt. 
In hoofdstuk I wordt een overzicht gegeven van de literatuur die op deze 
vragen betrekking heeft. Het blijkt dat ook meruit slechts weinig duidelijke 
antwoorden gedistilleerd kunnen worden. Zeker is wel dat de hypothalamus-
hypofyse-bijnieras bepaald en gereguleerd wordt door een gesloten negatief 
terugkoppelingssysteem. Er is reeds lang een grate hoeveelheid bewijsmateriaal 
- zij het voor een belangrijk dee! indirect - voorhanden, waaruit blijkt dat er 
stoffen bestaan die de afgifte van ACTH bevorderen. Tot voor kort was de 
exacte samenstelling hiervan onduidelijk maar recent werd een 'corticotropin 
releasing factor' (CRF) geisoleerd uit de hypothalami van schapen. Dit bleek 
een polypeptide met 41 aminozuren te zijn. Het lijkt echter waarschijnlijk 
dat bij andere diersoorten dergelijke stoffen, met een andere aminozuur samen-
stelling, ontdekt zullen worden en dat er geen sprake zal blijken te zijn van 
een 'universeel' CRF. 
In hetzelfde hoofdstuk word! ook een overzicht gegeven van de beschikbare 
literatuur betreffende het veronderstelde supprimerende effect van ACTH zelf 
op de afgifte van CRF: het zogenaamde 'short' loop negative feedback effect. 
Deze studies verschenen vooral in de jaren zestig en in het begin van de jaren 
zeventig, en bijna alle gegevens werden verkregen uit experimenten met ratten 
onder zeer bijzondere omstandigheden. Het blijft de vraag in hoeverre dit ver-
schijnsel ook in fysiologische omstandigheden van belang is. 
Het belang van neurotransmitters voor de synthese en afgifte van CRF is 
door vele auteurs overtuigend aangegeven. Dat cholinergische en adrenergische 
neuronen hierbij een rol spelen is reeds vrij lang bekend. 
Serotonine heeft de laatste jaren in toenemende mate de aandacht getrok-
ken als een neurotransmitter die een stimulerend effect op CRF kon hebben. 
ln dit onderzoek hebben wij ons als belangrijke vraag gesteld of het mogelijk 
zou zijn, met behulp van bestaande geneesmiddelen, die neurotransmitter 
activiteit zodanig te stimuleren, dat het supprimerend effect van hoge doses 
glucocorticoiden op de functie van de hypothalamus-hypofyse-bijnieras geheel 
zou worden voorkomen. 
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In hoofdstuk II wordt het model van de transplanteerbare, ACTH en pro-
lactine producerende, tumor 7315a beschreven. Met gebruik van dit model bij 
ratten was het mogelijk, het be lang van het reeds eerder genoemde 'short' loop 
negative feedback mechanisme na te gaan. Wij hebben aangetoond dat in dit 
model de hoge glucocortico.id concentratie in de circulatie de belangrijkste 
factor was die de negatieve terugkoppeling op de synthese en afgifte van ACTH 
bewerkstelligde. In dit model althans, hebben wij geen duidelijk bewijs kunnen 
vinden voor het bestaan van een terugkoppelingssysteem, waarin ACTH zelf 
een negatief effect he eft op de synthese en afgifte van CRF. 
In hoofdstuk Ill worden de experimenten bij ratten beschreven waarin ge-
poogd werd de hypothalamus-hypofyseas te stimuleren met behulp van stoffen 
met veronderstelde serotonergische en cholinergische effecten. Het manipule-
ren van de hypothalamus-hypofyseas slaagde met serotonergische stoffen 
aanzienlijk beter dan met cholinergische. Met name chlorimipramine (Ana-
frani!®) was in staat de suppressie van zowel de hoeveelheid ACTH in de 
hypofyse voorkwab, als de afgifte van ACTH aan de circulatie te voorkomen, 
in aanwezigheid van een hoge concentratie corticosteron. Het positief effect 
van fenfluramine (PonderaJ®) was minder uitgesproken. 
In hoofdstuk IV hebben wij in een prospectieve studie bij de mens het 
effect nagegaan van relatief hoge doses prednison op het functioneren van de 
hypothalamus-hypofyse-bijnieras. Het is duidelijk geworden dat prednison, 
zelfs wanneer dit slechts gedurende I 0 dagen gegeven wordt, een duidelijke 
suppressie van de functie van deze as bewerkstelligt. Bij enkele patienten kon 
het bestaan van een bijnierinsufficientie op biochemisch niveau worden aange-
toond. De met prednison behandelde patienten hadden tijdens een halsexplo-
ratie significant lagere cortisolwaarden dan een vergelijkbare groep controle 
patienten. 
Dit kan er op wijzen dat procedures die gepaard gaan met stress een po-
tenW~el gevaar opleveren, ook wanneer glucocortico"iden slechts gedurende een 
korte tijd toegediend worden. Anderzijds is gebleken dat het herstel van de 
functie van de hypothalamus-hypofyse-bijnieras ook weer snel intreedt: een 
dag na de operatie was de respons van de bijnier op stimulatie met ACTH weer 
geheel normaal. 
In hoofdstuk V tens lotte, worden de pogingen beschreven de functie van de 
hypothalamus-hypofyse-bijnieras te stimuleren door gebruik te maken van 
gelijktijdige toediening van prednison en chlorimipramine, analoog aan de 
desbetreffende experimenten in de rat. Voor zover ons bekend zijn er in de 
literatuur geen studies verschenen waarin getracht is de hypothalamus-hypofyse-
bijnieras te stimuleren door gebruik te maken van stoffen met neurotransmitter 
activiteit (met name serotonergische activiteit), teneinde suppressie van de as 
door glucocorticoiden te voorkomen. 
De veelbelovende resultaten, verkregen bij de dierexperimenten, zijn bij de 
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patienten die beide midde!en toegediend kregen niet gehee] geevenaard. Ener-
zijds werden er na toediening van chlorimipramine en prednison op biochemisch 
niveau geen tekenen meer gevonden van bijnierinsufficientie, zoals eerder bij 
de patienten die aileen met prednison behandeld werden. Bovendien was er 
een significant beter reactievermogen van de hypotha!amus-hypofyse-bijnieras 
na toediening van de chlorimipramine, wanneer dat geeva!ueerd werd met 
behulp van ACTH- en metopiron stimulatie testen. Anderzijds waren de plasma 
cortiso!waarden, noch tijdens de periode van 10 dagen waarin beide farmaca 
gelijktijdig werden toegediend, noch tijdens de operaties verschillend van de 
cortisolwaarden bij patienten die aileen prednison toegediend kregen. Wij zijn 
dus niet in staat geweest aile supprimerende effecten van glucocorticoiden te 
voorkomen. 
De meest voor de hand liggende verklaring is dat de dosis g!ucocorticoiden 
tach te hoog is om elke vorm van suppressie met behulp van deze dosis ch!or-
imipramine te voorkomen. 
Het is goed mogelijk dat het toedienen van g!ucocorticoiden in lagere do-
seringen, in combinatie met hogere doseringen van stoffen met serotoner-
gische eigenschappen zoa!s chlorimiprarnine en wellicht oak fenflurarnine, 
betere resu!taten oplevert. Niettemin suggereren onze studies bij de rat en de 
mens dat het mogelijk is de hypotha!amus-hypofyse-bijnieras te beinvloeden 
door gebruik te maken van stoffen die door hun neurotransmitter activiteit de 
synthese en afgifte van CRF kunnen stimuleren. 

Verantwoording 
Het schrijven van een proefschrift doet de aandacht te eenzijdig uitgaan naar de 
schrijver. Pas in de verantwoording, achterin opgenomen, blijkt hoezeer de 
auteur dank verschuldigd is aan a! diegenen die het onderzoek, het beschikken 
over de talloze laboratoriumfaciliteiten en het verrichten van de vele labora-
toriumbepalingen mogelijk gemaakt hebben. 
Zo ook in mijn geval. Dank uiteraard, in de eerste plaats aan rnijn promotor, 
Steven Lamberts die de stuwende kracht achter de totstandkoming van dit 
werk is geweest, en met zijn ongebreidelde energie, aanstekelijk enthousiasme 
en 'positief' denken rnij door de dieptepunten, zoals die in elk onderzoek 
voorkomen, heeft ge]eid. De vele uren die wij samen doorbrachten discus-
sierend over meer dan aileen dit proefschrift zijn voor mij van grate betekenis 
geweest. Mijn tweede promotor, Prof. Dr J.C. Birkenhiiger, die steeds met 
grate belangstelling en zijn vermaarde kritische instelling de totstandkoming 
van dit boekje begeleid heeft, ben ik bovena] dank verschuldigd voor de voor-
treffelijke en gevarieerde wijze waarop hij als mijn opleider en !eermeester de 
vorrning van een assistent ter hand genomen heeft. Zijn encyclopedische be-
langstelling maakt hem tot een - onbereikbaar- voorbeeld voor anderen. 
Mijn eerste wankele stappen op het pad van de ACTH-bepaling werden met 
altijd hulpvaardige, en soms kritische belangstelling gadegeslagen door de mede-
werkers van het laboratorium en de 4 Zuid zijvleugel: Ellen Bons, die mij aile 
laboratoriumwerk met vee! noodzakelijk geduld ge!eerd heeft, Piet Uitter-
linden, Rob Oosterom, Theo Verleun, Joke Zuiderwijk en Ronald Lammers 
die altijd bereid waren tot hulp bij de vele dierexperimenten. Aan hen allen 
zeer vee! dank. Uiteraard ook a an Dr G .H. Mulder die zo goed was ons de 
door hem ontwikkelde ACTH-bioassay ter beschikking te stellen. De zeer 
bewerkelijke procedures nodig voor de vele metopiron- en ACTH-stimulatie-
testen werden op voortreffelijke wijze verricht op de afdeling endocrinologie, 
4 Noord, door Zr Paula Schuyff en de haren, waarbij met name Zr Jean Heuff 
en Zr Cis Baarschens genoemd moe ten worden. De vermaarde organisatie van 
Zr Schuyff stand garant voor een perfecte afwikkeling van het gecompliceerde 
protocol. 
Dr Frank de Jong en zijn laboratoriumwerkers waren telkens bereid de 
honderden cortisol* en desoxycortisolmonsters met voorrang te bepalen. Ik 
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ben Dr de J ong bovendien dank verschuldigd voor zijn gewaardeerd commen-
taar. Dr H.A. Bruining tract steeds als 'vaste' chirurg open omzeilde enthousiast 
alle bestaande wachtlijsten om aan de regels van het protocol voor wat be-
treft de operaties te kunnen voldoen. Oak zijn spontane medewerk:ing en be-
langstelling heb ik op zijn grate waarde geschat. 
Bas van Ouwerkerk en Rini Baggen waren in 1983 tijdens de operaties aan-
wezig om de cortisolmonsters af te nemen. Laatstgenoemde was mij bovendien 
frequent op zaterdag en zondagochtend behulpzaam bij de injecties in de 
ratten, zij het in eerste instantie met gemengde gevoelens ten aanzien van de 
ratten. 
Mijn collegae in de maatschap interne van het Diakonessenhuis Refaja 
vingen mijn afwezigheid waar nodig open droegen bovendien in 10 maanden 
tijd liefst 3 van de 6 patienten met primaire hyperparathyreoidie aan, die in 
he! onderzoeksprotocol konden worden opgenomen. 
Anke de Graaff verrichtte op zeer nauwgezette en voortreffelijke wijze al 
het vele typewerk voor dit proefschrift; een zwaar en tijdrovend werk waarvoor 
mijn dank niet groat genoeg kan zijn. 
Tot slot, maar niet als minste, dankbaarheid ten aanzien van mijn moeder, 
die met mijn vader mogelijk gemaakt heeft, wat heden bereikt word!. 
Aan mijn vader is niettemin dit proefschrift opgedragen. 
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De schrijver dezes werd in 1951 in Rotterdam geboren. Aan het Gymnasium 
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te Utrecht. In juni 1972 volgde het candidaatsexamen, terwijl in februari 
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1976 behaald. Daarop volgde van maart 1976 tot oktober 1977 de dienstplicht 
bij de Koninklijke Marine. Op l januari 1978 werd de opleiding interne genees-
kunde aangevangen in het Majella Ziekenhuis te Bussum ( opleider Dr D. 
Maingay). Vanaf januari 1979 tot en met december 1982 werd de opleiding 
op de afdeling interne geneeskunde Ill van het Academisch Ziekenhuis Dijk-
zigt te Rotterdam (opleider Prof. Dr J.C. Birkenhager) voortgezet en afgerond. 
Dit proefschrift werd op dezelfde afdeling bewerkt. 
Sinds I januari 1983 is de schrijver als internist verbonden aan het Diakones-
senhuis Refaja te Dordrecht. 

